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Abstract 
Heart failure is a chronic disease responsible for over 11 million outpatient clinic 
visits each year. According to the Healthcare Cost and Utilization Project (2009), heart 
failure is one of the most frequent principal diagnoses utilized. Hypokalemia and 
hyperkalemia, which can be caused by some of the medications used to treat heart failure, 
are often associated with cardiac arrhythmias and sudden cardiac death. The researchers 
investigated healthcare provider compliance with the recommended 2009 American 
College of Cardiology Foundation/American Heart Association guidelines for monitoring 
routine serum potassium levels in heart failure patients. Sister Callista Roy's Adaptation 
Model was used as the conceptual framework to guide this study's assessment of 
healthcare providers' monitoring levels of serum potassium, our main intracellular 
electrolyte. Using a retrospective chart review, 200 charts from two rural primary care 
clinics in north and east central Mississippi were examined regarding the follow-up 
monitoring of potassium levels in heart failure patients. Participants were 18 years of age 
and older. 
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CHAPTER I 
Dimensions of the Problem 
Background 
Heart failure is a condition resulting in the loss or dysfunction of heart muscle. It 
is characterized by venous congestion, inadequate peripheral oxygen delivery, and 
ventricular dilation/hypertrophy which lead to circulatory abnormalities. This disease 
can occur as the result of impaired pumping of blood out of the heart, called systolic 
heart failure, or impaired relaxation of heart muscle, called diastolic heart failure. In 
some patients, abnormalities of both systolic and diastolic heart dysfunction can 
co-exist. 
Certain medications used in the treatment of heart failure, such as diuretics, 
angiotensin-converting enzyme inhibitors (ACE-I), angiotensin II receptor blockers 
(ARB), beta-blockers, and aldosterone antagonists, can have adverse effects on the 
body's potassium level. Fluid and electrolyte disorders accounted for 17% of the 
secondary diagnoses for heart failure in 2009, which was an increase from 11% in 1997 
(Wier et ah, 2011). An appropriate potassium level is needed to maintain the body's fluid 
balance, conduct nerve impulses and muscle contraction, and help prevent cardiac 
arrhythmias. Patients with heart failure should maintain a potassium level in the 
4.0-5.0 mEq/L range (Jessup et ah, 2009). An alteration of the potassium level, 
either hyperkalemia or hypokalemia, can affect a patient's cardiac conduction and 
excitability which can lead to sudden cardiac injury or death (Hunt et al., 2005). 
Hypokalemia, which is common in heart failure, can enhance cell membrane excitability 
and delay ventricular repolarization. Hyperkalemia, another common complication of 
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heart failure, can affect the repolarization phase of the heart and depress the contraction 
of the sinoatrial node. Both of these conditions predispose patients to cardiac 
arrhythmias, therefore increasing their mortality rate (Bowling et ah, 2009). 
Heart failure affects males and females, all age groups from children to the 
elderly, and all races. At 40 years of age, the lifetime risk for developing heart failure for 
both men and women is 1 in 5. At 80 years of age, the remaining lifetime risk for 
developing a new diagnosis of heart failure remains at 20%, despite the fact that the 
patient has a much shorter life expectancy (Roger et al., 2011). The incidence of heart 
failure increases with age. Statistical data demonstrates a fourfold increase in new 
diagnosis for Caucasian men greater than 85 years (Roger et ah, 2011). 
An estimated 6 million people in the U.S. have been diagnosed with heart failure, 
with over 670,000 new cases being diagnosed each year (Centers for Disease Control and 
Prevention [CDC], 2012). Nearly 1.4 million people 60 years of age and under have been 
diagnosed with heart failure, and African-Americans are 1.5 times more likely to develop 
this disease than Caucasians (Emory Healthcare Heart and Vascular, 2012). According to 
the Healthcare Cost and Utilization Project of 2009 (Wier et al., 2011), heart failure was 
listed among the top 10 most frequent principal diagnoses utilized. Heart failure can be 
contributed to approximately 287,000 deaths per year (Emory Healthcare Heart and 
Vascular, 2012). The Heart Failure Society of America (n.d.) reported that < 50% of 
patients will survive 5 years after the initial diagnosis of heart failure, with < 25% of 
patients surviving after 10 years of initial diagnosis. Sudden death is common in patients 
with heart failure, occurring at a rate of 6 to 9 times greater than the general population 
(Emory Healthcare Heart and Vascular, 2012). The diagnosis of heart failure is 
mentioned on 1 out of 9 death certificates in the U.S. (Roger et al., 2011). The poor 
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prognosis can be linked to a limited understanding of the disease process, prevalence of 
comorbid conditions, and socioeconomic status. 
Heart failure is responsible for 11 million outpatient clinic visits each year, and 
for more hospitalizations than all forms of cancer combined (Emory Healthcare Heart and 
Vascular, 2012). Heart failure accounts for nearly 875,000 hospitalizations and is the 
most common diagnosis documented in hospitalized patients 65 years of age and older 
(Emory Healthcare Heart and Vascular, 2012). The Prevention Quality Indicator for 
Heart Failure hospital readmission rates for 2009 indicated the highest rate is for 75 years 
of age and older, with approximately 2,500 per 100,000 people (U.S. Department of 
Health and Human Services Agency for Healthcare Research and Quality [AHRQ], 
2012). Groups of patients 65 to 74 years of age had a rate of approximately 840 out of 
100,000 people, 40 to 64 years of age had a rate of approximately 200 out of 100,000 
people, and 18 to 39 years of age had a rate of approximately 19 out of 100,000 people 
(AHRQ, 2012). 
The economic burden of managing heart failure in the U.S. can be overwhelming. 
Heart failure is a serious public health concern with a cost of approximately $40 billion 
from health services and medications, as well as the loss of productivity (CDC, 2012). 
An estimated $2.6 trillion was spent on health care in 2009, which represented more than 
17.6% of the gross domestic product for the U.S.; moreover heart failure expended more 
Medicare dollars than any other diagnosis (Dunlay et ah, 2010). The increased 
prevalence of heart failure can be illustrated by frequent hospitalizations, a growing 
mortality rate, a complex treatment regimen, and a rising financial and societal burden. 
Compliance with the 2009 American College of Cardiology Foundation/American 
Heart Association (ACCF/AHA) guidelines (see Appendix A) for monitoring routine 
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potassium levels with the management of heart failure could potentially decrease adverse 
cardiac outcomes (Jessup et ah, 2009). The Institutes for Clinical Systems Improvement 
(ICS!) Guidelines for Heart Failure in Adults (2011) (see Appendix B) further 
recommend that stable patients in the clinic setting should have electrolyte levels 
monitored at least every 4 months for the duration of the heart failure medication therapy. 
If an electrolyte imbalance is discovered, increased lab monitoring would be justified 
until levels return to normal. According to the AHRQ, patients may require 
hospitalization if their condition is not effectively monitored in the outpatient setting 
(2012). 
Problem Statement 
Despite many medical advances, the incidence of heart failure continues to rise. 
Heart failure adds to the economic burden in our country and greatly increases a patient's 
mortality rate. Certain medications used in the treatment of heart failure can have 
adverse effects on serum potassium levels. Because the lack of testing serum potassium 
levels can lead to life-threatening cardiac complications, it is important to ensure that the 
healthcare provider is monitoring serum potassium levels routinely in patients with a 
diagnosis of heart failure. 
Statement of Purpose 
The purpose of this study was to evaluate healthcare providers' compliance with 
the recommended 2009 ACCF/AHA guidelines for monitoring routine serum potassium 
levels in heart failure patients. The researchers of this study focused on the importance of 
monitoring routine serum potassium levels in heart failure patients at least every 4 
months. The results of this study could help healthcare providers effectively manage 
heart failure patients and possibly help prevent the development of life-threatening 
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complications. According to the guidelines and latest evidence-based practice, the 
healthcare provider should routinely monitor serum potassium levels. Devastating 
outcomes such as cardiac arrest can be the result of severe hypokalemia. 
Significance of the Study 
Heart failure is widely recognized as an increasingly common health problem 
associated with a high mortality rate. It can result from any condition that interferes with 
blood volume being sufficiently pumped from the heart. Potassium, the main 
intracellular electrolyte, plays a critical role in the heart's electrical conduction. Serum 
potassium levels affect cardiac automaticity and membrane excitability as well as 
repolarization (Bowling et ah, 2009). 
Many of the medications used in the treatment of heart failure can alter the body's 
potassium level. Other factors such as renal function can also affect potassium levels. 
Patients with heart failure should maintain a potassium level in the 4.0-5.0 mEq/L range 
(Jessup et ah, 2009). 
Efforts should be made by healthcare providers to routinely monitor for changes 
in serum potassium levels in order to help prevent potentially life-threatening cardiac 
arrhythmias. Data from the current research can be applied to show the importance of 
following the recommended 2009 ACCF/AHA guidelines for monitoring serum 
potassium levels in the treatment of heart failure. Following evidence-based guidelines 
has been considered to have substantial medical advantages. The healthcare provider will 
utilize these heart failure guidelines in the detection, prevention, and management of this 
condition. Critical evidence indicates that both hypokalemia and hyperkalemia may 
cause fatal arrhythmias. 
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The study by the current researchers provides data regarding compliance with the 
2009 ACCF/AHA guidelines, differences in treatment as evidenced by payer source, as 
well as age, sex, and ethnicity of participants. There is limited current information in this 
area of study. 
Theoretical Foundation 
Sister Callista Roy's Adaptation Model (RAM) will be used to guide this research 
study. This theory provides the framework that will assist in evaluating the role of the 
healthcare provider related to caring for a patient's physical, medical, social, and 
enviromnental issues associated with adapting to a chronic illness, such as heart failure. 
By utilizing this theory, the healthcare provider/patient relationship can be used to 
achieve a comprehensive approach to efficient and effective healthcare management. 
The RAM nursing theory views the individual as a holistic adaptive system as 
related to the concepts of person, health, environment, and nursing (George, 2011). It is 
aimed at understanding human behavior in order to maintain and enhance coping 
mechanisms to promote optimal health. The individual must have the ability to adapt to 
biological and psychological changes. 
Adaptation includes two control processes, the regulator and the cognator 
subsystem coping mechanisms (George, 2011). The regulator subsystem includes 
automatic reflexes through endocrine, neural, and chemical channels. The cognator 
subsystem processes are associated with perception and information processing, learning, 
judgment and emotion. The effects of the regulator and cognator processes interrelate 
and are measured by behavioral outcomes. Adaptation occurs when these subsystems are 
stimulated, causing a change in behavior measured in physiologic and psychosocial 
modes. 
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Adaptation can be grouped into four modes: physiological-physical, self-
concept/group identity, role function, and interdependence (George, 2011). The 
physiological mode represents the physical body and environmental interactions. It 
includes basic human needs such as oxygenation, nutrition and fluid balance, elimination 
patterns, activity and rest, and protection. The self-concept mode represents the 
maintenance of the psyche and spirit. It represents an individual's perceptions or beliefs, 
which are central to behavior responses. The role function mode represents social 
integrity. It represents an individual or group's adaptation to role changes. The 
interdependence mode also represents social integrity. It includes the personal 
relationships and the need for love, respect, and security. 
The individual is also continuously influenced by different types of internal and 
external stimuli (George, 2011). Focal stimulus is the most demanding situation and is 
perceived as an immediate concern. Contextual stimulus is an internal or external factor 
that will produce a positive or negative response. Residual stimulus is a factor, such as 
an attitude or habit, which can produce an uncertain effect. Observation of an 
individual's behavior can identify the effectiveness of his or her coping abilities. Coping 
mechanisms are viewed as either adaptive or ineffective. A provider should work with 
the patient in order to develop intervention goals needed to meet positive adaptive coping 
strategies. Monitoring serum potassium levels at least every 4 months and adjusting the 
medication regimen if the serum potassium level is not in the recommended range help 
the patient adapt to the effects of heart failure. Adaptive mechanisms are appropriate 
responses for strengthening positive actions. Ineffective mechanisms will prevent the 
individual's ability for effective change and promotion of health. 
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Research Questions 
Research questions were constructed to guide this investigation and assist in 
obtaining data. The study's objectives were to analyze the healthcare providers' 
documentation of routine monitoring of potassium levels in heart failure patients. The 
following questions were addressed: 
1. Was the serum potassium level in patients being treated for heart failure 
monitored and documented at least every 4 months as recommended by the 
ICSI Guidelines for Heart Failure in Adults? 
2. Was the potassium level in the recommended range of 4.0-5.0 mEq/L 
according to the 2009 ACCF/AHA recommended guideline when monitored? 
3. If the potassium level was not in the recommended range, was there a 
medication adjustment? 
Definition of Terms 
For the purposes of this study, the following terms were defined: 
Serum potassium 
Theoretical: A chemical element that serves as both the principal cation in 
intracellular fluid and an important electrolyte in extracellular fluid. It has many 
functions, including metabolism, cell membrane homeostasis, nerve conduction, 
and muscle contraction (Venes, 2001). 
Operational: Serum potassium lab values of heart failure patients 
obtained through retrospective chart reviews. 
Patient 
Theoretical: One who is sick with, or being treated for, an illness or injury; an 
individual receiving medical care (Yenes, 2001). 
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Operational: Person who has sought medical care at the primary care clinic on 
prior occasions before the retrospective review of their chart. 
Heart Failure 
Theoretical: The heart's inability to circulate blood effectively enough to meet 
the body's metabolic needs. Heart failure may affect the left ventricle, right ventricle, or 
both. It can result from the impaired ejection of blood from the heart during systole or 
from impaired relaxation of the heart during diastole (Venes, 2001). 
Operational: a condition that results in the loss of heart muscle leading 
to circulatory abnormalities. Patients with ICD-9 diagnosis code 428. 
ICSI Guidelines for Heart Failure 
Theoretical: Evidence-based healthcare guidelines developed by an independent, 
nonprofit healthcare improvement organization that unites clinicians, health plans, 
employers, policymakers, and consumers to improve health, optimize the patient 
experience, and make health care more affordable (Institute for Clinical Systems 
Improvement, 2011). 
Operational: Evidence-based guideline for heart failure in adults used by the 
current researchers as the recommended timeframe that serum potassium should be 
monitored. 
Recommended range 
Theoretical: The difference between the highest and lowest in a set of variables 
or in a series of values or observations (Venes, 2001). 
Operational: The difference between the lowest mEq/L of potassium (4.0 
mEq/L) and the highest mEq/L of potassium (5.0 mEq/L) a person with heart failure 
should have as stated by the ACCF/AHA (Jessup et ah, 2009). 
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ACCF/AHA guidelines 
Theoretical: Evidence-based health care guidelines developed by a group of 
medical professionals that have jointly engaged in critically evaluating the use of 
diagnostic procedures and therapies as they are introduced to effectively manage or 
prevent cardiovascular disease since 1980 (Jessup et ah, 2009). 
Operational: Evidence-based guidelines for the diagnosis and management of 
heart failure in adults, used by the current researchers as a guide for the recommended 
range of potassium as well as a medication regimen for patients diagnosed with heart 
failure, ICD-9 diagnosis code 428. 
Medication adjustment 
Theoretical: A medication change made to improve function or condition (Venes, 
2001). 
Operational: An increase or decrease of dosage or amount made in a patient's 
medication regimen, i.e. ace inhibitor, angiotensin receptor blocker, diuretic, or 
aldosterone antagonist that would be made due to a serum potassium level out of the 
recommended range. 
Hypokalemia 
Theoretical: An abnormally low concentration of potassium in the 
blood (Venes, 2001). 
Operational: A serum potassium lab value of heart failure patients 
< 4.0 mEq/L. 
Hyperkalemia 
Theoretical: An excessive amount of potassium in the blood (Venes, 
2001). 
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Operational: A serum potassium lab value of heart failure patients 
>5.0 mEq/L. 
Assumptions 
Clinical practice guidelines exist to help healthcare providers effectively manage 
heart failure. For the purpose of this study, the following assumptions were made: 
1. Healthcare providers are knowledgeable regarding the 2009 ACCF/AHA 
guidelines for monitoring serum potassium levels in the treatment of heart 
failure. 
2. Information concerning the serum potassium level, medications, age, gender, 
ethnicity and payer source is documented on the patient's charts. 
3. Documentation regarding heart failure diagnosis and treatments are sufficient 
for data collection. 
Limitations 
The limitations noted for this research study were as follows. 
1. The sample was limited to charts of adult patients, 18 years of age and older, 
being treated with a diagnosis of heart failure. 
2. Participants were selected from two rural primary care clinics in north and 
east central Mississippi, which limited the generalizability to a smaller 
geographic area. 
3. The provider's adherence to the guidelines relied on their documentation in 
the medical records from these two rural primary care clinics. 
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Summary 
Despite advances in pharmacological treatment, the prevalence of heart failure is 
on the rise. Inpatient and outpatient management of this condition exhausts more 
Medicare monies than any other diagnosis (Dunlay et al, 2010). An alteration in 
potassium levels, either hyperkalemia or hypokalemia, can greatly impact a heart failure 
patient's morbidity and mortality. The increased incidence of heart failure, in addition to 
complications caused by an alteration of potassium, supported the need for careful 
evaluation of these patients. The purpose of this study was to determine if healthcare 
providers are monitoring serum potassium levels in heart failure patients according to the 
2009 ACCF/AHA guidelines. Proper assessment, diagnosis, and treatment are needed to 
provide quality care to the heart failure patient. 
CHAPTER II 
Review of Literature 
Each year in the United States, more than 670,000 people are diagnosed with 
heart failure. A plethora of existing comorbidities, such as diabetes, hypertension, and 
hyperlipidemia, contribute to heart failure. Socioeconomic status, race, and culture of the 
population can be linked with progression of this deadly disease. The following review 
of literature supports the significance of appropriate treatment of heart failure. 
In a quantitative, non-randomized propensity-matched study conducted by Alper 
et al. (2009) data were collected from participants in a randomized trial in the early 
1990s. The researchers sought to determine the long-term effects of low serum 
potassium on mortality and hospitalization of older adults age 65 years and over 
diagnosed with chronic systolic and diastolic heart failure. The elderly are often 
excluded from clinical trials; therefore, existing data are limited in the > 65-year-old age 
group. 
The large randomized clinical trial was conducted during 1991-1993 in 186 U.S. 
and 116 Canadian locations. From the sample of 7,788 participants in the Digoxin 
Investigative Group (DIG) trial, 4,036 were 65 years of age or older. A total of 3,598 out 
of 4,036 had data on baseline serum potassium levels (Alper et al., 2009). After 
exclusion of participants with serum potassium > 5.0mEq/L, a subset of 3,274 individuals 
were identified. A total of 590 of the 3,274 participants had low potassium defined as 
serum potassium < 4.0 mEq/L, and 2,684 participants had normal potassium defined as 
4.0-4.9 mEq/L. Propensity score matching was used to balance the covariates between 
patients with low versus normal potassium. The researchers used a non-parsimonious 
multivariable logistic regression model to estimate propensity scores (Alper et al., 2009). 
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Propensity scoring tor hypokalemia was defined as the conditional probability of that 
participant developing hypokalemia given his or her baseline covariates (Alper et ah, 
2009). After matching, 1,670 participants had normal serum potassium levels of 4.0-4.9 
mEq/L, and 561 or 95% of the initial 590 had low serum potassium documented < 4.0 
mEq/L. 
For matching purposes with this model, the dependent variable was low-serum 
potassium. Baseline characteristics consisted of co-morbidities, medications, signs and 
symptoms, vital signs, diagnostic data, and information on gender and race. After 
matching, participants were studied to determine a relationship between hypokalemia in 
the elderly population and mortality or hospitalization. Alper et al. (2009) suggested that 
there are limited studies with this age group. Ten percent of the articles in the review of 
literature were published in the last 5 years, with approximately 45% in the last 10 years. 
Of the 31 articles in their literature review, 61% were published in journals of cardiology 
or heart-related journals. Surprisingly, only 6% were published in journals related to 
gerontology with other related journals accounting for the remaining 32%. The 
researchers identified that hypokalemia may be an indicator of disease progression. In 
addition to diastolic and endothelial dysfunction, an increased rate of thrombosis and 
platelet aggregation was associated with low potassium (Alper et al., 2009). 
Bias was avoided by estimating pre- and post-match absolute standardized 
differences of covariates between the two groups. "An absolute standardized difference 
of 0% indicated no residual bias, and an absolute standardized difference below 10% 
suggested inconsequential residual bias" (Alper et al., 2009, p. 2). In addition to having 
absolute standardized differences, McNemar and paired sample t tests compared the 
baseline characteristics of matched patients (Alper et al., 2009). "Kaplan-Meier plots and 
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matched Cox regression analysis were used to estimate associations of low potassium 
with various outcomes" (Alper et ah, 2009, p. 2). According to Alper et al. (2009), 
researchers used three different approaches to test for bias: unadjusted, adjusted for raw 
propensity scores, and adjusted for all covariates used in the propensity score model. In 
addition, they reviewed outcomes for the full pre-match cohort in an effort to show that 
decreasing the sample size of the larger study did not skew their data (Alper et ah, 2009). 
Findings from this propensity-matched study of ambulatory adults over 65 years of age 
diagnosed with heart failure and hypokalemia did have an increase in mortality but not 
hospitalization (Alper et ah, 2009). According to Alper et al. (2009), the dissociation 
between mortality and hospitalization may have been caused by preventable fatal 
ventricular dysrhythmias that precluded the hospital admission. 
This study's findings indicate that maintaining a normal serum potassium level of 
4.0-4.9 mEq/L in patients with chronic heart failure may improve their survival. They 
further stated that spironolactone or eplerenone may be preferable to a potassium 
supplement to correct hypokalemia in chronic heart failure patients. A strength identified 
in this study was the degree to which the researchers went to match and analyze the data 
to avoid any bias or misrepresentations. Weaknesses identified included the lack of data 
on dosages of diuretics, magnesium levels, or sudden cardiac deaths (Alper et al., 2009). 
This study is significant to the current researchers; interest shows the importance 
of monitoring the serum potassium levels and regulating within the desired range of 4.0-
4.9 mEq/L for patients diagnosed with heart failure. Many labs consider 3.5-5.0 mEq/L 
normal for most healthy individuals. This study reveals a tighter control of 4.0-4.9 
mEq/L is needed to prevent fatal dysrhythmias for patients diagnosed with heart failure. 
This study supported the importance of maintaining electrolyte levels within an 
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acceptable range in order to prevent hyperkalemia, which could cause detrimental effects 
if not controlled. 
In a study conducted by Desai et al. (2007), hyperkalemia was indicated as a 
serious adverse event in patients diagnosed with heart failure. It can cause many 
complications ranging from medical intervention to lethal cardiac arrhythmias. Adequate 
renal perfusion is needed to help maintain normal potassium levels through sodium 
reabsorption, maintaining normal aldosterone concentrations and normal potassium 
channels in the collecting duct system (Desai et al., 2007). A decreased renal function, 
associated with age and comorbid conditions, can lower the body's ability to excrete 
potassium. Certain medications can also increase the probability of developing 
hyperkalemia. Angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor 
blockers (ARB), and mineralocorticoid receptor antagonists can reduce morbidity and 
mortality with heart failure patients but can increase serum potassium levels (Desai et al., 
2007). 
Quantitative data obtained in the Candesartan in Heart Failure-Assessment of 
Reduction in Mortality and Morbidity (CHARM) Program was utilized to perform a 
retrospective analysis of the incidence and predictors of hyperkalemia with a median 
follow-up of 3.2 years. The CHARM Program defined clinically important hyperkalemia 
as hyperkalemia requiring medical intervention, such as medication dose reduction, study 
drug discontinuation, hospitalization, or death (Desai et al., 2007). The researchers 
utilized the Mantel-Haenszel method to determine the incidence of hyperkalemia, 
compare treatments, and calculate variable duration, f he Cox proportional hazards 
model was used to analyze the timing for development of hyperkalemia requiring medical 
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intervention. The Cox model was also used to analyze multivariate predictors, such as 
age, gender, medication, and diabetes. 
The CHARM Program was compromised of 7,599 participants who were treated 
according to standard heart failure guidelines in addition to randomized treatment with a 
titrated dose of the ARB candesartan, or placebo. The CHARM Program researched the 
benetit and risks of using candesartan, alone and in combination with an ACE inhibitor 
(Desai et al., 2007 ). Hie choice of the ACE inhibitor was determined according to the 
preference of the investigator with the dosage based on proven clinical trial effectiveness 
in addition to patient tolerance. The researchers identified a CHARM Program North 
American cohort subset of 2,675 eligible male and female patients, age 18 years and 
older, who were diagnosed for at least 4 weeks with symptomatic class II to IV heart 
failure according to New York Heart Association Classification guidelines (Desai et al., 
2007). 
Patients were evaluated at 2, 4. and 6 weeks; 6 months; and then every 4 months 
until the conclusion of the study. The investigators performed serial monitoring of lab 
values including potassium and creatinine levels in addition to close observation for 
serious complications, such as hyperkalemia. According to Desai et al. (2007), lab values 
were assessed prior to the initiation of the medication, again within 2 weeks after the 
medication dose was stabilized, then yearly. Ihe investigators also had the option of 
performing additional lab monitoring according to their discretion. 
The investigators determined that heart failure patients at risk for developing 
hyperkalemia, 12.6 per 1,000 patient-years, were males of advanced age with a history of 
diabetes, as well as those using an ACE inhibitor or spironolactone. It was also noted 
these patients had a baseline potassium level of 5.0 or greater and creatinine of 2.0 or 
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greater. The patients at greater risk were those with baseline renal insufficiency, 
accounting for more serious hyperkalemia events including hospitalization or death 
(Desai et al., 2007). The investigators also concluded patients with creatinine levels of 
2.0 or above receiving the placebo were twice as likely to develop hyperkalemia as those 
patients with creatinine levels < 2.0 who were receiving the ARB candesartan (Desai et 
al., 2007). The investigators concluded serious hyperkalemia episodes occurred in 2.7 
per 1,000 patient-years, although the rate could have been elevated to 11.9 per 1,000 
patient-years if effective monitoring protocols had not been followed (Desai et al., 2007). 
Desai et al. (2007) reported inhibitors of the renin-angiotensin aldosterone system 
(RAAS) can decrease potassium excretion, especially in patients with compromised renal 
function. Drugs that can hinder the production or action of renin and angiotensin include 
non-steroidal anti-inflammatory drugs, beta-blockers, ACE inhibitors, and ARBs. When 
used in effective doses, RAAS inhibitors have been noted to reduce morbidity and 
mortality outcomes; however, potassium levels can be increased < 1 mEq/1 (Desai et al., 
2007). Spironolactone, an aldosterone receptor antagonist, has also been associated with 
hyperkalemia, including associated hospitalizations. 
Several limitations were identified by the researchers. Potassium monitoring 
guidelines were furnished to the CHARM investigators; however, the decision to manage 
the hyperkalemia and report it as an adverse event was left to the judgment ot the 
investigator. The definition of clinically important hyperkalemia was not assigned actual 
serum potassium values; therefore, the researchers considered the possibility that some 
physicians may have managed a tolerable increase in the potassium level or that some 
increases in potassium level could have gone undetected. Anothei limitation identified 
was that although dose reduction or discontinuation of candesartan due to hypeikalemia 
was reported for the trial, hospitalization and death were only identified by investigator-
reported adverse event review (Desai et ah, 2007). 
Further studies in larger cohorts are needed for more precise hyperkalemia 
occurrence rates; however, a strength identified by the researchers was the data provided 
by the CHARM Program provided important information regarding hyperkalemia risk in 
the management of patients with heart failure. Desai et al. (2007) concluded the periodic 
laboratory testing of serum potassium level and creatinine level is important to reducing 
adverse events related to hyperkalemia (Desai et ah, 2007). 
The research study conducted by Desai et al. (2007) was significant to the current 
study of monitoring potassium levels in the treatment of heart failure since it studied the 
incidence and predicting factors that are associated with hyperkalemia events associated 
with heart failure treatments. Their findings found that hyperkalemia occurred in a large 
group of heart failure patients, whether or not they were taking the ARB medication 
candesartan (Desai et al., 2007). Certain populations were identified as having a higher 
occurrence risk for developing clinically important hyperkalemia. Male patients aged 75 
years and older, with a decline in renal function and comorbid medical conditions, have 
an increased risk of developing hyperkalemia. Patients with a low left ventricular 
ejection fraction were found to be more likely to develop hyperkalemia as opposed to 
patients with a left ventricular ejection fraction of 40% or greater (Desai et al., 2007). 
The practitioner must understand the affecting risk factors in order to be able to carefully 
weigh the benefits of treatment options as it relates to morbidity and mortality rates for 
heart failure. Careful monitoring of labs should be perfoimed to help pi event the 
development of hyperkalemia in patients treated with heait failuie medications. 
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Bowling et al. (2009) performed a quantitative, propensity matched study that 
investigated the effects of hypokalemia on patients suffering from chronic heart failure 
with the comorbidity of chronic kidney disease (CKD). Sampling data used in the 
current study came trom the Digitalis Investigative Group (DIG), a randomized clinical 
trial, conducted in the early 1990s. The DIG study consisted of 7,788 patients diagnosed 
with chronic heart failure and chronic kidney disease (CKD). Prior research had shown 
that hypokalemia and CKD were associated with poor outcomes in heart failure patients. 
The researchers evaluated the effect hypokalemia has on patients suffering from both 
heart failure and chronic kidney disease. 
Of the 7,788 ambulatory patients with chronic systolic and diastolic heart failure 
in normal sinus rhythm enrolled in the DIG trial, 6,800 had a left ventricular ejection 
fraction < 45% (Bowling et ah, 2009). More than 90% of DIG participants were 
receiving angiotensin-converting enzyme inhibitors, and close to 80% were receiving 
non-potassium sparing diuretics. Patients with a serum creatinine > 2.5 and serum 
potassium > 5 were excluded from the study. After exclusion of the creatinine and 
potassium in those ranges, a cohort of 6,278 patients was available for analyses (Bowling 
et al., 2009). The researchers further broke down this cohort into those who had chronic 
kidney disease. Of the 6,278 patients, 2,793 had a glomerular filtration rate (GFR) < 60 
mL/min per 1.73 m2 body surface area (Bowling et al., 2009). Of the 2,793 with CKD, 
527 had hypokalemia (serum potassium < 4 mEq/L), and 2,266 had normokalemia (4.0-
4.9 mEq/L) (Bowling et al., 2009). Of particular interest to the current study, using a 1-
to-1 greedy matching protocol, the current researcheis matched 522 heart failure patients 
with hypokalemia to 522 heart failure patients with normokalemia who had similar 
propensity scores (Bowling et al., 2009). This study also reviewed patients that were 
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considered severely hypokalemic with a serum potassium <3.5 and advanced stages of 
CKD with a GFR < 45 mL/min per 1.73 m2 (Bowling et al., 2009). In addition to the 
aforementioned, thiee additional cohorts were assembled within the current research. 
The dependent variable in the study was the presence of hypokalemia. There were 32 
measured baseline characteristics and 2 covariates, creatinine by diuretic use and 
creatinine by angiotensin-converting enzyme inhibitor use (Bowling et al., 2009). In 
addition to information on age, race, and gender, the baseline characteristics consisted of 
diagnostic and radiology results, signs and symptoms, and other objective data. The 
researchers were interested in hypokalemia versus normokalemia in the heart failure 
patients with CKD as it pertained to all-cause mortality, cardiovascular mortality, and 
hospitalizations. The study found that all-cause mortality occurred in 48% and 36%, 
respectively, of all 522 patients with hypokalemia versus normokalemia in chronic heart 
failure and CKD (Bowling et al., 2009). Cardiovascular mortality for patients with 
hypokalemia was 39% as compared to 28% of those with normokalemia. Mortality 
related to progressive worsening heart failure was 21% in the hypokalemic patient as 
compared to 14% in the normokalemic patient (Bowling et al., 2009). All-cause 
hospitalization for heart failure patients with hypokalemia was 72% as compared to 69% 
with normokalemia. Cardiovascular hospitalization lor hypokalemia and normokalemia 
was 59% and 53%, respectively. Hospitalization related to worsening heart failure was 
39% in the hypokalemic patient versus 34% in the normokalemic patient. The 
researchers further showed that even mild hypokalemia as defined by serum potassium of 
3.5-3.9 in this study and considered normal by many textbooks can be significant to the 
patient diagnosed with heart failure. All-cause mortality for the patient with mild 
hypokalemia was 47% as compared to 38% of the patients with normokalemia, defined as 
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serum potassium 4.0-4.9. All-cause cardiovascular mortality was 39% for the mildly 
hypokalemic patient versus j0% with normokalemia. Thirty percent of the patients with 
mild hypokalemia expiied from worsening progressive heart failure versus 13% of those 
with normokalemia. Sixty-five of the 522 patients in this study had more severe 
hypokalemia as defined by serum potassium levels below the 3.5 mEq/L range. Thirty-
one percent of patients with severe hypokalemia died from events related to worsening 
heart failure in comparison to 14% of those with normokalemia. The theoretical 
framework used in the study was not evident; however. Roy's Adaptation Model (RAM) 
by nurse theorist Sister Callista Roy could be considered here. This theory can be applied 
because of the physiological-physical mode, one of four adaptive modes identified by 
Roy. This mode consists of the need for fluid and electrolyte balance along with the 
process of maintaining homeostasis of the body's internal environment. 
The statistical analysis was performed using SPSS version 15 for Windows, a 
computerized statistical package. For descriptive analyses, the researchers used Pearson 
X2 and Wilcoxon rank sum tests for the pre-match data and the McNemar test and paired 
sample t test for post-match comparisons. Kaplan-Meier plots and matched Cox 
regression were used in estimation of hypokalemia with other outcomes. To determine 
the homogeneity of hypokalemia with all-cause mortality among patients with heart 
failure and CKD, the researchers examined the association in various subgroups of 
matched patients (Bowling et ah, 2009). 
Due to this study being conducted through a retrospective chart review, the 
researchers did not interact with participants from the DIG trial. Therefore, no data were 
outlined in the study as to how the participant's rights were affected. A particular 
weakness identified was the exclusion of data on the dosages of diuretics. The inclusion 
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of dosing regimens would have been an added strength (Bowling et ah, 2009). Many 
believe that the signs and symptoms of heart failure are strongly associated with the 
dosage of the diuietic. Another limitation to this study was that no data were provided on 
the B-type natiiuietic peptide levels (BNP) which could have provided further 
information on the severity of heart failure (Bowling et ah, 2009). In addition to absence 
ol data regarding the BNP, no data existed on the use of beta-blockers due to the fact that 
they were not approved at the time of the original research from which this dataset was 
extracted. Strengths of the study were to bring attention to the public and healthcare 
professionals about the imperative monitoring of serum potassium levels in heart failure 
patients with CKD. "In ambulatory patients with chronic heart failure and CKD, 
hypokalemia is associated with increased mortality and hospitalization. Research shows 
that even mild hypokalemia defined as 3.5-3.9 for heart failure patients with CKD are 
associated with poor outcomes" (Bowling et ah, 2009, p. 259). 
This article statistically shows the percentage of mortality and hospitalizations 
related to both mild and severe hypokalemia. "Hypokalemia is known to enhance 
membrane excitability, increase cardiac automaticity, delay ventricular repolarization and 
predispose patients to reentrant arrhythmias" (Bowling et ah, 2009, p. 258). For this 
reason, it is imperative that practitioners follow the guidelines to maintain the potassium 
levels of heart failure patients between 4.0-5.0 mEq/Liter. Serum potassium should be 
monitored and maintained in this range to avoid even mild hypokalemia in patients with 
heart failure that also have chronic kidney disease. Ihe importance of iollowing cuiient 
heart failure guidelines combined with a thorough physical exam piotocol toi the general 
medical profession is imperative in order for continuity of care and preventative 
treatment outside the hospital setting. 
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In a study by Aranda, Johnson, and Conti (2009). heart failure was shown to 
affect approximately 5 million adults in the United States. In 2008 heart failure costs 
were an estimated $J4 billion. The researchers concluded that 12 to 15 million office 
visits and 6.5 million yearly hospital days can be attributed to heart failure, despite 
improv ements in treatment with medications, such as angiotensin-converting enzyme 
inhibitors, B-blockers, and aldosterone antagonists. Patients hospitalized with a 
diagnosis of heart failure are at a higher risk for readmission within 6 months—as high as 
50% (Aranda et ah, 2009). 
The investigators utilized a retrospective, observational study to estimate current 
rates of readmission for Medicare patients with heart failure, identify the reasons for 
these readmissions, and identify associated factors related to increased risk of 
readmissions. The information was gathered from 2002-2004 Medicare data obtained 
from the Centers for Medicare and Medicaid Services. Although previous studies on 
readmission rates have been useful, those results have often been limited to single-center 
experiences which are not representative to the general population current practices. 
According to Aranda et al. (2009), a 5% sample was created by selecting records with a 
health insurance claim number ending in 05, 20, 45, 70, or 95. This type of sampling 
technique provided consistency, allowing the researchers the ability to identify records 
associated with the same beneficiary across several years. All patient information, 
recorded by a calendar-year quarter, included hospital dischaige during 200J with an 
ICD-9 discharge code of 428.0 through 428.9 (heart failure) or 398.91 (lheumatic heait 
failure). 
Aranda et al. (2009) limited baseline patient characteristics to age, gender, race, 
comorbidities, and geographical location. Other baseline characteristics considered were 
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previous hospitalizations, length of stay for the initial heart failure hospitalization, 
implantation ol a pacemaker or cardioverter-defibrillator during the initial heart failure 
hospitalization (Atanda et ah, 2009). A multivariate logistic regression method was 
utilized to examine the associations between the baseline characteristics and rates of 
readmission. Readmission rates within each of the characteristics were compared after 
calculating odds ratios. 
The researchers' investigation identified 28,919 patients which totaled 38,849 
heart failure hospitalizations in the 2003 Medicare sample. The identified patient data 
revealed 51% with one or more hospitalizations for any cause in the 6 to 9 months prior 
to the first heart failure hospitalization. Patients with a previous heart failure 
hospitalization in the preceding calendar year totaled 18%, while 6% of patients had two 
or more previous heart failure hospitalizations. Utilizing this information, the researchers 
were able to predict an estimated 776,980 hospitalizations involving 578,380 patients 
(Aranda et ah, 2009). 
According to Aranda et al. (2009), heart failure accounted for the most frequent 
reason of all hospital readmissions, totaling 28% during the review period. 1 he patients 
in the 65 years and older age group comprised 89% of the sample selection. The data 
also revealed that 83% were Caucasian, 56% were female, and 37% had a comorbidity of 
diabetes. Patients who resided in the southern region of the United States totaled 41%, 
which was the highest of any demographic rate. 
The researchers used a multivariate logistic regression model to identity factois 
associated with readmission for any cause within 6 to 9 months of the initial heart failure 
hospitalization. Aranda et al (2009) determined that 60% of the patients had at least one 
readmission, with an average of 2.2 readmissions noted per patient. The data revealed 
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patients >ounger than 65 years of age had a decreased probability of readmissions within 
6 to 9 months as compaied with patients 65 to 85 years of age. Caucasian patients had a 
higher risk foi readmission as compared to minority patients. Patients diagnosed with 
heart taiiure had a highei occurrence of comorbidities, which will also influence 
readmission lates. However, findings of the study indicated that patients diagnosed with 
hypertension, or those who received an implanted cardiac device at the time of the initial 
heart failure hospitalization, had a lower risk of readmission (Aranda et al., 2009). The 
population included in this study had a mean length of stay of 5.4 to 5.5 hospital days. 
1 he researchers also determined the patients in the sample population had a 4.4% in-
hospital mortality rate, and approximately 8% of the patients that were not readmitted 
died within the first 6 to 9 months after the initial heart failure hospitalization (Aranda et 
al., 2009). 
One of the study's limitations identified by the researchers was that there was a 
lack of extensive clinical information which prevented detailed evaluations, such as 
identifying New York Heart Association (NYHA) classification or disease severity. 
Another limitation identified was that the information from the sampling of Medicare 
claims in the Medicare Standard Analytical File Limited Data Set did not provide an 
exact date of each hospitalization, making it difficult to identify discharges in 2003. 
Although this is done to help protect patient privacy, it can lead to certain challenges 
when a patient had other hospitalizations during the same calendai-yeai quaitei (Aianda 
et al., 2009). 
The strength of this study was the use of a large public health database to identify 
current trends in healthcare, such as readmission rates for heart failure patients. This 
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resource can help identify associated factors that lead to poor outcomes after the initial 
heart failure hospitalization (Aranda et ah, 2009). 
The ieseaich study conducted by Aranda et al. (2009) was important to the current 
study of monitoring potassium levels in the treatment of heart failure. The study 
confirms that despite improved medication options and evidence-based treatment 
guidelines, heart failure patients continue to experience an increased chance for disease 
exacerbation. Aranda et al. (2009) concluded that individuals with heart failure have a 
60% hospital readmission rate, as well as significant mortality rate. It is important for the 
healthcare provider to identify this high-risk population in order to decrease the 
possibilities of comorbidity events, such as monitoring alterations in potassium levels 
which could cause life-threatening arrhythmias. Therefore, increased awareness and 
education are needed for the appropriate treatment of heart failure patients, while at the 
same time helping decrease the economic burden associated with this disease. 
In a study conducted by Dunlay et al. (2010), heart failure is an ever-increasing 
economic burden on the United States healthcare system. Medical care costs have risen 
over the years and are projected to continue to rise partly due to an aging population, a 
rise in the diagnosis of heart failure, and additional co-morbid conditions. Heart failure 
treatment constituted an estimated $37 million in 2009 and consumed more U.S. 
Medicare dollars than any other diagnosis (Dunlay et al., 2010). Despite what is known 
about hospitalization care costs, much less is known about the cost of outpatient medical 
care. 
Dunlay et al. (2010) investigated the estimated lifetime costs from heart failure 
diagnosis until death. The study was conducted in Olmsted County, Minnesota, from 
1987 to 2006. Medical records from 97% of the population involving all care sources 
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were indexed and linked in a centralized system known as the Rochester Epidemiology 
Project database. This database contained medical record information and billing 
information tor hospitalization, surgery, and outpatient visits. 
This cohoit longitudinal study identified residents with a diagnosis of heart 
failure using the ICD-9 code 428. Patients were excluded from the study if heart failure 
was diagnosed prior to the study period or diagnosed before moving to the county. 
Records were reviewed by abstractors to ensure that all criteria and diagnosis 
documentation were present. A total of 1,054 heart failure patients were randomly 
sampled. The baseline characteristics of the population were 46.1% male with a mean 
age of 76.8 years. The mean follow-up was conducted at 4.6 years and found that 765 
patients had died (Dunlay et al., 2010). 
After cases were identified and grouped into the appropriate heart failure 
category, the lifetime costs data were estimated using the 2-part Tian and Huang method. 
The first part of the model estimated the probability of having positive costs. The second 
part of the model uses generalized linear methods to pattern the lifetime costs in the event 
of positive cost. A similar 2-part model was used to determine the independent 
predictors of lifetime costs by predicting inpatient, outpatient, and total costs (Dunlay et 
al., 2010). 
The investigators' data revealed 77% of the costs were due to hospitalization with 
an average of $73,762 per person, while outpatient costs averaged $22,032 per person 
with the highest proportion stemming from evaluation, management, and piocedures in 
the provider's office. Certain co-morbid conditions, such as (a) hypertension, (b) renal 
disease, (c) COPD, (d) anemia, (e) diabetes mellitus, and (f) cerebrovascular disease, 
which could lead to or exacerbate heart failure, were found to increase the costs. The 
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researchers determined that the distribution of costs were high at the time of initial 
diagnosis and decreased and remained relatively low until the end stage of the heart 
failure disease process when costs increased again. The investigators further analyzed 
the cost effect by comparing healthcare costs in the year prior to the diagnosis of heart 
failure with the year beginning with the diagnosis. A mean total cost of $8,000 per 
pet son was noted piior to the diagnosis, with a marked increase of a mean total cost of 
$34,000 per person in the year after diagnosis (Dunlay et al., 2010). 
One limitation to the study was the fact that the researchers identified only direct 
medical care in interpreting the data. The investigators did not include indirect costs of 
care or outpatient medications in research. Another limitation identified was that some 
costs may have been underestimated if a patient received medical care outside the 
community due to travel or other extenuating circumstances. Although the researchers 
did not compare lifetime costs of care with a control group of patients without heart 
failure, there is evidence of a marked increase in the costs of care post-diagnosis of heart 
failure in the same patients as compared to before the diagnosis. The researchers also 
acknowledged that the results related to a single geographical area; however, the ability 
to examine lifetime costs of medical care in a stable population provides valuable 
information. Despite the limitations identified, the researchers acknowledged this study's 
importance in determining the distribution of resources and cost and various patient 
characteristics that can predict high or low costs. The strengths included the use of a 
validated population of heart failure patients followed longitudinally and the inclusion ot 
both inpatient and outpatient costs of healthcare costs (Dunlay et al., 2010). 
The research study conducted by Dunlay et al. (2010) further supported the 
significance of conducting the current study of monitoring potassium levels in the 
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treatment of heart failure by identifying factors associated with higher medical costs. 
This can be helpful in targeting patients in order to carefully prevent or treat certain co-
morbid conditions, improve quality of care, and avoid inpatient admissions to help reduce 
healthcare costs. 1 his study suggested these are key areas for the practitioner to focus 
appropriate medical intervention in the treatment and management of heart failure. 
Fonarow et al. (2012) performed a mixed study with a nested matched case-
control design using data retrieved through retrospective chart review. The current study 
obtained data from the longitudinal, cohort study, Registry to Improve the Use of 
Evidence-Based Heart Failure Therapies in the Outpatient Setting, known as (IMPROVE 
HF). IMPROVE HF is one of the largest heart failure studies. There has been limited 
research exploring the application of guideline-recommended therapy with clinical 
outcomes in patients with heart failure (Fonarow et al., 2012). The researchers in this 
study sought to discover the individual and incremental gains associated with each of 
seven current guideline-recommended therapies for heart failure and reduced left 
ventricular ejection fraction (LVEF) (Fonarow et ah, 2012). The seven guideline-
recommended therapies consisted of the following: (a) angiotensin converting enzyme 
inhibitor or angiotensin receptor blocker (ACEI/ARB), (b) beta-blocker, (c) aldosterone 
antagonist, (d) anticoagulation for atrial fibrillation/flutter, (e) cardiac resynchronization 
therapy (CRT) with a pacemaker or defibrillator, (f) implantable cardioverter-defibiillator 
(ICD or CRT with defibrillator), and (g) patient education about heart failure (Fonarow et 
al., 2012). 
The researchers sought to define the significance or value of each individual 
therapy as recommended by the guidelines. The primary analysis was designed to 
evaluate the association of baseline use of the seven guideline-recommended heart failure 
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therapies and mortality within 24 months and follow-up" (Fonarow et ah, 2012, p. 18). 
In addition, the researchers measured the probability of death in patients eligible for 
therapy versus those not receiving any treatment. Investigators sought to determine the 
association between the total number ol guideline-recommended therapies received by all 
patients at baseline and death within 24 months (Fonarow et al., 2012). The sequential 
contribution of ACEI/ARB, beta blockers, cardiac ^synchronization therapy (CRT), and 
ICD were analyzed. A defined theory was not explicit. 
The population of patients from which the current study derived was 15,177 of the 
original participants enrolled in IMPROVE HF. Eligibility criteria to participate in the 
study included a clinical diagnosis of heart failure or prior myocardial infarction, with a 
LVEF < 35%. Initially, a random sample beginning with approximately 90 participants 
from 167 clinics across the United States was available prior to propensity matching. 
The sample of participants for this current study was 4,128 after the propensity score 
matching process. This sample was then divided into two groups: (a) those that had 
expired from any cause before 24 months and (b) those alive at 24 months. The 
participant group which expired was defined as cases, and the group alive at 24 months 
was referred to as controls. The sample of 4,128, after division into cases and controls, 
were 1,376 and 2,752, respectively. Propensity score matching on the case and control 
groups was completed using a 1:2 greedy-matching. Between the two groups, the 
participants were well-matched with race being the only statistically significant 
difference (Fonarow et ah, 2012). The majority of the outpatient practices was not 
affiliated with a university or teaching facility and was well-matched with the number of 
individuals on staff (Fonarow et ah, 2012). The probability of death was the propensity 
score in this analysis. A logistic regression model was used to generate the probability of 
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death. The outcome consisted of deceased versus those alive. Covariates consisted of 22 
baseline patient characteristics and 4 practice characteristics. "Patients who met the 
guideline eligibility criteria for each individual therapy, with no contraindications, 
intolerance, or other documented reasons for not receiving it, were eligible for inclusion 
in the analyses for that measure" (Fonarow et al., 2012, p. 18). To qualify for an 
aldosterone antagonist, CRT, or ICD therapy, documentation of the New York Heart 
Association functional class must exist in the medical record (Fonarow et al., 2012). 
Chart reviewers received training from members of the IMPROVE PIF committee to 
ensure abstraction ot data was accurate (Fonarow et al., 2012). A report on data was 
generated on a monthly basis during data collection over the 24-month period. In 
addition, an audit was completed on 20% of all participant data. Thorough matching and 
education of chart reviewers helped to avoid bias. However, socioeconomic factors or 
patient adherence to therapeutic regimens could not be adjusted (Fonarow et al., 2012). 
The two-sample t test and chi-square test were used for analysis of the continuous 
variables and categorical variables, respectively. Baseline treatment rate was calculated 
for the case and control groups. Differences between the two were compared using the 
chi-square test (Fonarow, et al. 2012). Initially, "an unadjusted odds ratio (OR) of death 
was determined using a logistic regression model with the therapy the predictor variable 
and no covariate adjustment" (Fonarow et al., 2012, p. 18). Further analysis to identify 
potential covariates was completed with the use of a univariate logistic regression model 
(Fonarow et al., 2012). Characteristics with a value < .10 in the univariate regression 
were fit into a multivariate regression model with treatment as the main etiect. 1 hetapies 
were listed in order of how commonly prescribed in clinical practice from greatest to 
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guidelines recommend serum potassium monitoring with the use of these medications. 
Without monitoring ot potassium by healthcare providers in patients prescribed these 
medications, a patient may die as a result of serious electrolyte abnormalities. Fonarow 
et al. (2012) stated that independently valuing heart failure therapies would enable a 
provider to make the best decision on which medicine to continue or discontinue if a 
choice must be made for leasons of cost, tolerance, or adherence. In addition, many 
hospitals and clinics provide performance improvement programs to ensure that 
guideline-recommended therapies are utilized. 
Conceptual Framework 
Several studies have focused on the use of Sister Callista Roy's Adaptation 
model. The innovative work of Sister Callista Roy, RN, PhD. presented the nursing 
theory that views the individual as a holistic adaptive system as related to the concepts of 
person, health, environment, and nursing. Roy's Adaptation Model (RAM) is aimed at 
understanding human behavior in order to maintain and enhance coping mechanisms to 
promote optimal health. RAM can be applied not only to the individual, but it can be 
easily adapted to group situations. The current research group reviewed one original 
article by Sister Callista Roy and three additional research articles using the Roy 
Adaptation Model as the theoretical framework. The current researchers demonstrated 
how these researchers utilized Roy's Adaptation Model to guide their studies as well as 
discuss how the Roy Adaptation Model was used as the foundation of the current 
research study. 
As a graduate student in 1964, Sister Callista Roy saw the person as an entity, 
which not only persisted on the individual self, but included the environment as a whole 
contributing to the health and well-being of the person holisticallv. She believed that the 
portal to human health was not only for nurses to care for the person physically but to 
incorporate environment, beliefs, roles, economics, and population-based care into the 
equation. Nursing exists as an academic discipline and a practice profession, and both 
rely on timely knowledge development. People of today's society have evolving needs 
that increase the complexity of care, such as a) chronic illnesses due to increasing 
longevity, (b) rising ethnic and racial populations, and (c) global economic status. Nurses 
must work for the common good and dignity of people within their realm of existence. In 
order to accomplish this task, Roy reevaluated the RAM to bring nursing care into the 
21 century and beyond. "The social mandate of nursing is to contribute to the good of 
society by knowledge-based practice related to contemporary and emerging health needs" 
(Roy, 2011, p. 1). Roy devised Epochs to extrapolate past thought to modern times in 
order to describe the needs and thoughts relevant to each Epoch period. Roy integrated 
Laszlo's view of the human brain when he described it as a quasi-neural energy-
information-processing network into a view of nursing around the globe that interacts 
with each other, to nature, and reality. This allows existing and future nurses to view the 
increasing role of knowledge expansion and care expectations placed on the nursing 
society as a whole. In addition, it allows nurse practitioners to build upon the solid 
foundation of knowledge that has been established in previous years tor use in today s 
21st century. 
Thomas (2007) reviewed a study on how self-concept has negative impacts on 
treatment modalities in patients with heart failure. Although there have been many 
surgical and medical advances in heart failure, pool adherence to recommended diet, 
exercise, and medication regimens continue to negatively impact outcomes (Thomas, 
2007). The RAM was used to guide this study in which Roy emphasized that self-
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concept or the perceptions that one holds of oneself directs behavior. Roy identified five 
different aspects on self-concept which include body image, body sensation, self-ideal, 
self-consistency, and moral-ethical-spiritual self (Thomas, 2007). A descriptive 
correlational design was used to assess if there was a correlation between self-concept 
and treatment modality compliance. Two heart failure clinics were included in the study. 
One clinic was located in a rural/suburban area, and the other was located in a large urban 
inner city (Thomas, 2007). Patients who met criteria for the study were asked questions 
as they visited the clinics. Descriptive and predictive correlational analysis, using the 
Pearson product moment correlation and the stepwise multiple regression were used to 
analyze the answers. The overall threat to self-concept was 12% (p < .01), threat to body 
image was 14% (p < .01), challenge to self-concept was 13% (p < .01), and challenge to 
moral-ethical-spiritual self and body image was 14.5% (p < .01) with the challenge to 
moral-ethical-spiritual self and body image being the strongest predictor of adherence to 
health regimens (Thomas, 2007). Using a theory-based nursing study helps us 
understand how self-concepts influence treatment modalities for HF patients. In addition, 
it identifies the imperative need for positive reinforcement, praise, and education. 
Abbas, Schahanz, and Saeed (2011) embarked on a study in Iran using RAM in 
attempts to describe the adherence to therapeutic regimens in patients with heait tailuie. 
As described in a previous study using the RAM, noncompliance to heart lailure 
treatment has become global. A descriptive correlational study was conducted in two 
medical centers in Iran with questionnaires filled out by paiticipating patients who met 
the qualifying criteria. Results showed the following analysis: 33% were female with 
average age 62 years, 80.6% were married, 56.9% used medications, 54.9% did not use 
medications, and 39.0% exercised. The findings of this study showed that a viewed 
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threat to the components of self-concept (including body sensation, body image, self-
consistency, self-ideal, and moral-ethical-spiritual self) has a negative relationship with 
regimen adherence, whereas a viewed challenge to self-concept and its components is 
positively related to the adherence (Abbas et al„ 2011). Nurses around the world should 
assess the outcomes ot this study and others as well in order to involve patients in their 
treatment regimens. Sistei Callista Roy has modernized the RAM to incorporate a more 
consistent global lesponse between all members of the medical profession in order to 
tonn a smoother transition from a noncompliant society due to decreased knowledge of 
the disease process and treatments to a better educated and involved compliant society. 
Bakan and Akyol (2007) did an interesting study that examined the effectiveness 
ot a RAM as a useful guide for nursing practice when caring for heart failure patients. 
The researchers utilized data from a secondary analysis of a randomized-controlled trial 
to determine how programs such as education, exercise, and social support impacted 
adaptation in patients with heart failure (Bakan & Akyol, 2007). The information was 
obtained by utilizing the Minnesota Living with Heart Failure Questionnaire. The study 
was directed by the RAM, which focused on environmental stimuli and the associated 
response modes to those stimuli (Bakan & Akyol, 2007). The four biopsychosocial 
modes used to measure the level of adaption are physiological mode, self-concept mode, 
role function mode, and interdependence mode. The authois established that patients 
with physical, emotional, social, and economic difficulties can have impaired coping 
mechanisms. Intervention groups for the four modes of adaptation were established to 
monitor and improve coping mechanisms. RAM is an important theory concept guide in 
the care of patients who have been diagnosed with heart failure. This article corroborates 
the need to incorporate RAM into patient education programs to enhance the patient's 
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knowledge and skills necessary to evoke behavior changes for appropriate coping of this 
long-term health problem. Using the Roy Adaptation Model, patients who had 
participated in the intervention group had improved emotional status and quality of life, 
increased functional abilities, and enhanced social support (Bakan & Akyol. 2007). 
Adaptation involves coping mechanisms to control internal and learned 
environment. The mechanisms for coping can be learned or inherited (George, 2011). 
R°y developed the concept of control mechanisms. Through her model, she classifies 
these mechanisms of coping as subsystems of the person's adaptive function (George, 
2011). Of significance to the current research project are the regulator and cognator 
subsystems and the physiological-physical mode, one of four developed by Roy's model. 
Rogers and Keller (2009) stated the effects of coping at the subsystem level cannot be 
measured. "The cognator subsystem involves four cognitive channels: perceptual and 
information processing, learning, judgment and emotion" (Rogers & Keller, 2009, para. 
8). Noncompliance with medication adherence and follow-up for serum potassium 
monitoring could be a result of cognitive impairment. Three components of the regulator 
subsystem include input, internal process, and output. It contains transmitters that can be 
characterized as chemical, neural, or endocrine. Work of breathing and regulatory 
feedback mechanisms of respiration and heart rate, the regulator subsystem, can be 
evident in patients with heart failure. Fluid and electrolyte balance, oxygenation, 
activity/rest and nutrition are complex processes of the physiological-physical mode. 
Rogers and Keller (2009) stated that, "stimulation to the regulator and cognator 
subsystems result in behavior changes measuied in the physiologic and psychosocial 
modes" (para. 8). Through monitoring of the potassium level in patients with heart 
failure and bringing an increased awareness to the national guidelines, the current 
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researchers will identify how providers can stabilize the internal environment. In 
addition, patients must be able to cognitively process information discussed with them on 
heart failuie education. Neurologically, their memory must be intact with an appropriate 
attention span. They must be able to adhere to follow-up visits for the monitoring of their 
potassium level, oui main intracellular electrolyte. Through the current study, these 
researchers will be more aware of our future patients' need for regulation of potassium 
levels and the need to positively reinforce follow-up. 
Summary 
The need to monitor serum potassium level is shown to be clinically significant in 
the outpatient setting. The review of literature clearly demonstrates that without 
providers monitoring the body's main intracellular electrolyte, death could occur. 
Evidence shows that ventricular arrhythmias could cause sudden death or increased 
mortality related to either hypokalemia or hyperkalemia. The 2009 ACCF/AHA 
guidelines should be followed by all providers in the outpatient setting with routine 
monitoring of all heart failure patients. 
CHAPTER III 
Design and Methodology 
The locus ol this study was to evaluate healthcare providers' compliance with the 
recommended 2009 ACCF/AHA guidelines for monitoring routine serum potassium 
levels in heart failure patients. An alteration in potassium levels, either hyperkalemia or 
hypokalemia, can cause severe cardiac arrhythmias. The results from this study could 
help healthcare piovideis ettectively manage heart failure according to the guidelines and 
prevent life-threatening complications that can affect heart failure patients. 
I he occurrence ot primary care providers' monitoring potassium levels in the 
treatment ot heart failure was determined by using a nonexperimental, quantitative 
design. Data were retrospectively obtained from a population sample of 200 charts of 
adult patients, 18 years of age and older, with the diagnosis of heart failure, ICD-9 
diagnosis code 428. The data were collected from the patient's electronic medical record. 
A standardized data collection worksheet was implemented to obtain all information. 
Specific data concerning the serum potassium level, frequency of collection, medication 
utilized, medication adjustment done if the serum potassium was out of range, age, 
gender, ethnicity, and payer source were obtained. In order to maintain the facility s 
records and ensure that each patient's right to privacy and confidentiality weie pieserved, 
all data collection will be conducted in a designated area of the facility. 
Population, Sample, and Setting 
The population in this study was any adult patient with the diagnosis of heart 
failure identified with ICD-9 diagnosis code 428. Only adult patients, 18 years of age 
and older, with a diagnosis of heart failure were selected for the evaluation of potassium 
monitoring. The researchers manually obtained a convenience sample of 200 charts from 
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two rural primary care clinics in north and east central Mississippi with an ICD-9 
diagnosis code 428. 
Implementation of the Project 
Protection of human rights. Prior to the collection of data, the researchers 
received written approval by the Mississippi University for Women's Institutional 
Review Board (IRB) (see Appendix C). Consent was obtained from the two primary care 
clinics in north and east central Mississippi where the data was collected for this study. 
The researchers obtained informed consent from each facility's director via a consent 
letter (see Appendix D) identifying the purpose and nature of the study. This research 
was retrospective chart review only and involved no disclosure related to human 
participants. Patient confidentiality was maintained at all times. Access to medical 
record numbers, names, date of birth, diagnosis, and other personal information was 
limited to the researchers. The research data collection worksheet (see Appendix E) 
contained no personal information, such as name, date of birth, or social security number. 
Data obtained from the data collection worksheet were stored on two password-protected 
media drives that were purchased explicitly tor this purpose. 
Data collection procedure. Utilizing the medical records, the researchers 
performed a query and collected a list of patients with an ICD-9 diagnosis code 428. 
Only charts with ICD- 9 diagnosis code 428 for heart failure were selected for review in 
this study. The data were obtained from charts of documented medical care provided to 
patients with heart failure. After the list was collected, the researchers manually 
reviewed a convenience sample of the first 200 medical records meeting the sample 
criteria for this study. 
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Once the sample was selected, a chart audit was performed using the standardized 
data collection worksheet to obtain data for sample inclusion. The researchers completed 
the chart reviews in a secluded area of the clinic. This area allowed privacy and did not 
impede patient flow. The data collection worksheets were stored on two password-
protected media drives purchased explicitly for this purpose. Each researcher remained 
in possession ot her tespective media drive and kept it in a locked box for safekeeping. 
The password was only known to the researcher. After the data had been compiled and 
the completed data collection worksheets were no longer needed, the media devices and 
worksheets were destroyed. 
Instrumentation. The researchers developed a standardized data collection 
worksheet. This worksheet allowed the following information to be collected in a 
systematic method: (a) diagnosis of heart failure; (b) the serum potassium level; (c) 
frequency of collection; (d) medications to include ARBs, ACE-I, aldosterone antagonist, 
diuretics (potassium-sparing, loop, or thiazide), and beta-blockers; (e) was a medication 
adjustment made if the potassium level was out of the recommended range; (f) age; (g) 
gender: (h) ethnicity; and (i) payer source. The data collection worksheet was used to 
evaluate each patient's chart for eligibility of inclusion in the sample. This data 
collection worksheet was utilized solely for the purpose of this reseaich study. 
Data Analysis 
After compilation, data pertaining to the research questions were analyzed using 
descriptive statistics. The researchers utilized assistance of a professional statistician to 
further correlate categorized percentiles and frequencies to answer the research questions. 
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Summary 
The importance ot monitoring routine potassium levels in the treatment of heart 
failure needs to be emphasized. Once consent from the two rural primary care clinics in 
north and east central Mississippi was obtained to conduct the study, the researchers 
performed a nonexperimental, descriptive retrospective chart review on 200 medical 
charts. 1 he sample w as chosen by use of a convenience sample. Confidentiality and 
protection of human rights were maintained at all times. The researchers utilized a data 
collection worksheet to gather information needed for descriptive statistics and 
correlation analysis to answer the research questions. Data were gathered from the 
patient records and analyzed descriptively to answer each of the research questions. The 
nominal data were accumulated and presented to a statistician or entered into a computer 
database for analysis. 
CHAPTER IV 
Research Findings 
The purpose of this study was to evaluate healthcare providers' compliance with 
the recommended 2009 ACCF/AHA guidelines for monitoring routine serum potassium 
levels in heart failure patients. In addition, the researchers evaluated if the routine serum 
potassium level was documented at least every 4 months as recommended by the ICSI 
Guidelines for Heart Failure in Adults. In this chapter, the sample will be described and 
the research questions will be answered utilizing the findings from the study. 
Profile of Study Participants 
A convenience sample of 200 charts ( N  =  200) with an ICD-9 diagnosis code 428 
was obtained from two rural primary care clinics in north and east central Mississippi. 
The data were manually extracted and recorded on a data collection worksheet designed 
by the researchers. Charts were not selected earlier than 2009 due to ACCF/AHA 
updated guidelines. Subsequent analyses of the data were performed using Minitab 
statistical software, version 16. The population sample was eligible for inclusion in the 
study when data collection instrument criteria were met. 
The sample population included both male and female individuals 18 years of age 
and older. The mean for the ages collected was 75 years, with ages ranging from J5-98 
years. The median age of the data set was 78 years. 
Participant Characteristics 
The first question on the researchers' data collection worksheet was in regard to 
gender. The sample consisted of 51.5% females ( n  = 103) and 48.5% males ( n  = 97). 
Figure 1 illustrates the percentage of the gender in the sample population. 
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Figure I .  Gender of sample population (TV = 200). 
1 he second question on the researchers' data collection worksheet was in regard 
to age. 1 he sample consisted of patients between the ages of 35 and 98 years. The mean 
age was 75 years. No patients with an ICD-9 diagnosis code 428 in the age range of 18-
30 years were identified. Ages 31 -50 years consisted of 4.5% (n = 9), ages 51 -70 years 
consisted of 26% (n = 52), and ages 71 and greater consisted of 69.5% (n = 139) of the 
sample. Figure 2 demonstrates the age range of the sample population. 
The third question on the researcher's data collection worksheet was in regard to 
ethnicity. Of the sample collected, 79.5% (n = 159) were Caucasian, 20% (n = 40) were 
African American, and 0.5% (n = 1) were other. No Flispanic patients with the ICD-9 
diagnosis code 428 were identified. Figure 3 depicts the ethnicity of the sample 
population. 
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C a u c a s i a n  A f r i c a n  A m .  
H i s p a n i c  O t h e r  
Figure 3. Ethnicity of sample population. 
The researchers also assessed the sample population's payer source on the data 
col l e c t i o n  w o r k s h e e t .  O f  t h e  s a m p l e  c o l l e c t e d ,  9 2 %  ( n  =  1 8 4 )  h a d  M e d i c a r e ,  0 . 0 1 5 %  ( n  
= a) had Medicaid, 0.06% (n = 12) had commercial insurance, and 0.005% (n = 1) was 
self-pay. Table 1 is used to illustrate these findings. 
Table 1 
Payer Source of Sample Population 
Payer source % 
Medicare 92.000 
Medicaid .015 
Commercial insurance .060 
Self-pay .005 
Results of Data Analysis 
According to the 2009 ACCF/AHA guidelines, patients with heart failure, ICD-9 
diagnosis code 428. should have routine monitoring of serum potassium levels. The 
recommendations state the serum potassium level should be maintained between 4.0-5.0 
mEq/L. 
The ICS I Guidelines for Heart Failure in Adults were utilized to define routine 
monitoring as at least every 4 months. If the serum potassium level was not in the 
recommended range of 4.0-5.0 mEq/L, the researchers assessed if there was a medication 
adjustment. The following figures will illustrate the statistical findings of the research 
questions. 
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Research question 1. Was the serum potassium level in patients being treated for 
heart tailuie monitoied and documented at least every 4 months as recommended by the 
Institutes for Clinical Systems Improvement Guidelines for Heart Failure in Adults? Of 
the 200 charts reviewed, 187 had documentation of a serum potassium level checked in 
the past four months. 1 his corresponds to a 93.5% compliance rate with the 
recommendation by the ICSI Guidelines for Fleart Failure in Adults. Figure 4 is used to 
illustrate these findings. 
Non-compl iance  
Figure 4. Frequency of serum potassium documentation. 
Research question 2. Was the serum potassium level in the recommended range 
of 4.0-5.0 mEq/L according to the 2009 ACCF/AHA recommended guideline when 
monitored? Of the 187 charts reviewed in which a serum potassium level was checked 
within the pas, 4 months. 142 charts had a documented serum potassium level between 
4.0-5.0 mEq/L. This represents 75.9% compliance with the recommended range, and 
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24.1% (n 45) outside the recommended range. Figure 5 is used to illustrate the 
findings. 
• Between 4.0-5.0 mEq/L Outside the recommended range 
24.1% 
Figure 5. Percentage of patients' serum potassium level within the recommended 
range. 
Research question 3. If the serum potassium level was not in the recommended 
range, was there a medication adjustment? Of the 45 charts reviewed in which the seium 
potassium level was outside the recommended range. 55.6% (n — 25) of the patients did 
receive a medication adjustment. The remaining 44.4% (n — 20) ol the patients did not 
receive a medication adjustment. Figure 6 is used to illustrate the findings. 
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Figure 6.  Percentage of patients outside the recommended range receiving a 
medication adjustment. 
Conclusion of Findings 
1 he data collected in the retrospective chart review was analyzed using 
descriptive statistics. This study utilized both tables and figures to present and describe 
the findings. Of the 200 charts reviewed. 93.5% (n = 187) of the sample population had 
documentation of a serum potassium level within the last 4 months. Of the 187 patients 
with documentation of a serum potassium level, 24.1% (n = 45) had a serum potassium 
level outside the recommended range of 4.0-5.0 mEq/L. However, out of the 45 patients 
who were not within the recommended range, only 55.6% (n — 25) received a medication 
adjustment to help correct the electrolyte imbalance. In conclusion, the primary care 
providers had a 93.5% compliance with serum potassium monitoring and medication 
adjustment if needed according to the 2009 ACCF/AHA guidelines in regard to the total 
sample population (N = 200). However, this study revealed there is an opportunity 
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among healthcare pio\ iders lor improvement in the routine monitoring of serum 
potassium level. 
CHAPTER V 
1 he Outcomes 
Implications 
I lean failure is a common complication of heart disease as a result of damage to 
the heart muscle. It is a chronic, progressive condition in which the heart muscle 
becomes too weak to efficiently pump an adequate amount of blood to meet the body's 
need toi blood and oxygen. Increasing prevalence, hospitalizations, and death rate have 
made CI If a major chronic condition affecting all ages and races. A review of literature 
was completed and demonstrated that heart failure is an overwhelming disease in the 
United States affecting millions. Also, it revealed that suboptimal treatment relates to 
increased hospitalization and office visits. According to the Healthcare Cost and 
Utilization Project of 2009, heart failure was listed among the top 10 most frequent 
principal diagnoses utilized (Wier et ah, 2011). Many medications used in the treatment 
of heart failure can alter the body's serum potassium level. Potassium plays a critical role 
in the heart's electrical conduction, affecting cardiac automaticity and membrane 
excitability, as well as repolarization (Bowling et ah, 2009). Heart failure patients should 
maintain a serum potassium level in the 4.0-5.0 mEq/L range to help prevent potentially 
life-threatening cardiac arrhythmias (Jessup et ah, 2009). 
The purpose of this study was to evaluate healthcare provider's compliance with 
the recommended 2009 ACCF/AHA guidelines for monitoring routine serum potassium 
levels in heart failure patients. In addition, the researchers evaluated if the routine serum 
potassium level was documented at least every 4 months as recommended by the ICSI 
Guidelines for Heart Failure in Adults. Sister Callista Roy's Adaptation Model was 
utilized as the theoretical framework for this study. This chapter will discuss the 
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importance of the findings, limitations of the study, implications for nursing, and 
recommendations for further research and practice. 
Interpretation of the Findings 
The sample (yV = 200) included patients >1 8 years of age who received care at one 
oi the two rural primary care clinics in north and east central Mississippi and had a 
diagnosis ot heart lailure with an ICD-9 diagnosis code of 428. The sample was 
p r i m a r i l y  c o m p r o m i s e d  o f  C a u c a s i a n s  ( n  =  1 5 9  o r  7 9 . 5 % ) ,  w i t h  a l m o s t  e q u a l  m a l e  ( n  =  
97 oi 48.5 %) and female (n = 103 or 51.5%) participants. The mean age was 75 years 
with ages ranging from 35 to 98 years. The primary payer source was Medicare (n = 184 
or 92%). 
The research project was guided by the following questions: 
1. Was the serum potassium level in patients being treated for heart failure 
monitored and documented at least every 4 months as recommended by the 
Institutes for Clinical Systems Improvement Guidelines for Heart Failure in 
Adults? 
2. Was the potassium level in the recommended range of 4.0-5.0 mEq/L 
according to the 2009 ACCF/AHA recommended guideline when monitored? 
3. If the potassium level was not in the recommended range, was there a 
medication adjustment? 
According to these findings, healthcare providers have a 93.5% compliance rate 
with monitoring and documenting the serum potassium level as recommended by the 
2009 ACCF/AHA Guidelines for the management of heart failure and the ICSI 
Guidelines for Heart Failure in Adults. However, these findings reveal there is a need 
among healthcare professionals for continued improvement in this critical area in the 
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treatment. Patients with heart failure should be carefully monitored for changes in serum 
potassium level. Every effort should be made to prevent the occurrence of either 
hypokalemia or hyperkalemia, both of which may adversely affect cardiac excitability 
and conduction leading to cardiac arrhythmias and sudden death. 
1 he review ot literature indicated the importance of routine monitoring of serum 
potassium levels and regulating within the desired range of 4.0-5.0 mEq/L for patients 
diagnosed with heart failure. If the acceptable range is not maintained, an alteration of 
serum potassium could cause detrimental effects. Age, gender, and ethnicity can be 
linked with progression of this deadly disease. 
Alper et al. (2009) sought to determine the effects of an alteration of serum 
potassium on older adults age 65 years and over diagnosed with heart failure. The 
investigators suggested that there were limited studies with this high-risk age group 
although the incidence of heart failure increased with age. The data revealed from the 
sample of 7,788 participants, 4,036 were 65 years of age or older. Ambulatory adults 65 
years of age and older diagnosed with heart failure and hypokalemia had increased 
adverse effects and mortality rate. The current research study revealed that 139 of the 
200 charts (69.5%) reviewed were 71 years and older. The current study correlates with 
the importance of healthcare providers identifying certain high-risk populations, 
especially the elderly, in order to decrease the possibilities of an alteration in the serum 
potassium level. 
Fonarow et al. (2012) identified the significance for following guideline-
recommended therapies in the treatment of heart failure. Without monitoring of serum 
potassium levels by healthcare providers in patients prescribed certain medications used 
in the treatment of heart failure, serious electrolyte abnormalities can develop. These 
abnormalities can lead to cardiac arrhythmias anrl rl(=>Qtn tv annyinmias and death. The current study correlates the 
need tor increased awareness and education in the appropriate treatment of heart failure 
patients. Although the data revealed a 93.5% compliance rate following the current 
guidelines in regard to monitoring serum potassium levels, it was also shown that 
improvement in this area is still needed to improve quality of patient care, reduce 
mortality rate, and lessen the economic burden caused by this disease. 
Limitations of the Study 
Limitations were identified in this study including the fact that data were only 
collected from two primary care clinics within the state of Mississippi which may not 
adequately represent diversity of the population. Another limitation is the serum 
potassium level may have been performed at a specialty office with no results forwarded 
to the primary healthcare provider leaving the charts with missing or inaccurate data. In 
addition, this study did not identify the reason why a medication adjustment was not done 
when the serum potassium level was not within the recommended range of 4.0-5.0 
mEq/L. Finally, the various class of medications used to treat heart failure was not 
evaluated for their potential effects on serum potassium level. 
Implications for Nursing 
This study is significant to the nurse practitioner tole because theie aie established 
guidelines for managing heart failure which represent evidence-based practices that 
healthcare providers are expected to utilize. Sister Callista Roy's Adaptation Model was 
used to guide this research study by influencing the relationship between the healthcare 
provider and patient. This enhanced relationship encouraged the patient to develop 
positive adaptive coping mechanisms leading to a comprehensive, holistic approach to 
care. 
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Heart failure has an increasing prevalence and high mortality rate which has led to 
a growing economic burden to the U.S. at an estimated $40 billion. By performing 
routine monitoring of serum potassium level at least every 4 months, an alteration outside 
the recommended 4.0-5.0 mEq/L range can be detected and interventions, such as a 
medication adjustment, can be implemented to help prevent the development of possible 
cardiac complications. 1 hrough this study, nurse practitioners were made aware of the 
importance ot adhering to the 2009 ACCF/AHA guidelines for monitoring routine serum 
potassium levels in heart failure patients. 
Recommendations for Research and Education 
Further research can be conducted by replicating this study with an increased 
number of clinical sites and a larger sample size to more adequately represent the 
population. This would reveal if more healthcare providers are following the 2009 
ACCF/AHA guidelines for monitoring routine serum potassium levels in heart failure 
patients. A special computer alert for the electronic health record could help ensure that 
heart failure patients had a timely evaluation of potassium levels. 
The authors believe that provider education is the best way to improve 
compliance in monitoring serum potassium levels in heait failuie patients. An 
educational in-service, presented to healthcare providers, may increase knowledge and 
compliance with the 2009 ACCF/AHA heart failure guidelines. In hopes that healthcare 
providers will realize the importance of following recommended guidelines, the authors 
plan to present the outcomes of this study to the two rural primary care clinics in which 
the data were collected. 
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Summary of Implications 
Certain medications used in the treatment of heart failure can alter the body's 
serum potassium level. A serum potassium level outside the recommended range of 4.0-
5.0 ml.q L in heart iailuie patients can increase adverse cardiac outcomes which can lead 
to potentially lile-threatening arrhythmias. The purpose of this study was to determine if 
healthcare providers were adhering to the 2009 ACCF/AHA guidelines for monitoring 
serum potassium levels in heart failure patients. The study revealed that of the 200 charts 
reviewed for the lirst research question 187 patients had documentation of a serum 
potassium level within the past 4 months. For the second research question, the authors 
determined that 45 out of those 187 patients or 24.1% had a serum potassium level 
outside the recommended range of 4.0-5.0 mEq/L. The research findings further 
concluded that 25 of the 45 patients who were not within the recommended range or 
55.6% received a medication adjustment to help correct the electrolyte imbalance. In 
conclusion, healthcare providers were 93.5% compliant with the 2009 ACCF/AFIA 
guidelines. If recommendations from this study are applied to practice, heait failuie 
patients would receive optimal healthcare decreasing the potential of life-threatening 
complications and decreasing outpatient clinic visits and hospitalizations. This could 
help improve the quality of life for heart failure patients and reduce the economic burden 
of managing heart failure in the U.S. 
REFERENCES 
Abbas. H„ Schahanz, A.. & Saeed, V. (2011). The relationship between self-concept and 
adherence to therapeutic regimens in patients with heart failure. 
Cardiovascular Nursing, 26(6), 475-480. doi.org/10.1097/JCN. 
ObOl3e318215bb78 
Alper, A. B„ Campbell. R. C„ Anker, S. D„ Bakris, G„ Wahle, C., Love, T. E„ Hamm, 
[ " L Ahmed, A. (2009). A propensity-matched study of low serum 
potassium and mortality in older adults with chronic heart failure. International 
Journal of Cardiology, 137, 1-8. doi.org/10.1016/j.ijcard.2008.05.047 
Aranda, J.. Johnson, J., & Conti, J. (2009). Current trends in heart failure readmission 
rates: Analysis of Medicare data. Clinical Cardiology, 32(1), 47-52. doi: 
10.1002/clc.20453 
Bakan. G., & Akyol. A. (2007). Theory-guided interventions for adaptation to heart 
failure. Journal of Advanced Nursing, 61(6), 596-608. doi.org/10.1111 /j. 13 65-
2648.2007.04489.x 
Bowling, C.B., Pitt, B., Ahmed, M. I., Aban, 1. B., Sanders, P. W., Mujib, M., Campbell, 
R. C., Love, T., . . . . Ahmed, A. (2009). Hypokalemia and outcomes in 
patients with chronic heart failure and chronic kidney disease: Findings from 
propensity-matched studies. Circulation of Heart Failure, 3, 253-260. 
Centers for Disease Control and Prevention. (2012). Heart failure fact sheet. Retrieved 
from http://www.cdc.gov/DHDSP/data_statistics/fact_sheets/fs_heart_failure.htm 
Desai. A., Swedberg, K., McMurray, J., Granger, C., Yusuf, S., Young, J., . . . . Pfeffer, 
M. (2007). Incidence and predictors of hyperkalemia in patients with heart failure 
An analysis of the CHARM program. Journal of the American College of 
Cardiology, 50(20), 1959-1966. doi.org/10.1016/j.jacn2007.07.067 
Dunlay, S. M., Shah. N. D„ Shi, Q., Morlan, B., VanHouten, H„ Long, K. L., & Roger, 
V. L. (2010, Decembei). Lifetime costs of medical care after heart failure diagnosis. 
Circulation: Cardiovascular Quality and Outcomes, 4, 68-75. doi: 10.1161/ 
CIRCOUTCOMES. 110.957225 
Emory Healthcare Heart and Vascular. (2012). Heart failure statistics. Retrieved from 
www.emory.org/heart-failure/learn-about-heart-failure/statistics.html 
fonarow, G. C.. Albert, N. M., Curtis, A. B., Gheorghiade, M., Liu, Y., Mehra, M. R., 
& Yancy. C. W. (2012). Incremental reduction in risk of death associated with 
use of guideline-recommended therapies in patients with heart failure: A nested 
case-control analysis of IMPROVE HF. Journal of the American Heart 
Association, 7(1), 16-26. doi.org/doi:10.1161/JAHA.l 11.000018 
George, J. B. (2011). Roy Adaptation Model. In M. Connor (Ed.), Nursing theories: The 
base for professional nursing practice (6th ed., pp. 291-337). Upper Saddle River, 
NJ: Pearson Education. 
Heart Failure Society of America, (n.d.). Quick heart failure facts. Retrieved from 
http:/Avww.hfsa.org/heart failure facts.asp 
Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, 
j 0 Riegel, B. (2005). ACC/AHA 2005 guideline update for the diagnosis 
and management of chronic heart failure in the adult: A report of the American 
College of Cardiology/American Heart Association Task Force on Practice 
Guidelines' Developed in collaboration with the International Society for Heart 
and Lung Transplantation. Circulation, doi: 10.1161/CIRCULAT10NAHA. 
105.167586 
Institute for Clinical Systems Improvement. ( 2 0 1 1 ) .  Health care guidelines: Heart failure 
in adults. Retrieved from http://www.icsi.org/heart_failure_2/heart_failure_in_ 
adults .html 
Jessup, M., Abraham, W. T., Casey, D. E., Feldman, A. M., Francis, G. S.„ Ganiats, T. 
G., Mancini, D. M. (2009). 2009 Focused update: A.CCF/AHA guidelines 
tor the diagnosis and management of heart failure in adults: A report of the 
American College of Cardiology Foundation/American Heart Association Task 
Force on Practice Guidelines: Developed in collaboration with the International 
Society for Heart and Lung Transplantation. Circulation, doi: 10.1161/ 
CIRCULATION AHA. 109.192064 
Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Adams, R. J., Berry, J. D., Brown, T. M., 
.... Wong, N. D. (2011). Heart disease and stroke statistics 2011 update: A 
report from the American Heart. Circulation, 123(e\ 14-el 19). doi: 10.1161/CIR. 
0b013e3182009701 
Rogers, C„ & Keller, C. (2009). Roy's Adaptation Model to promote physical activity 
among sedentery older adults. Geriatric Nursing, 30(2), 21-26. doi.org/10.1016/ 
j.gerinurse.2009.02.002 
Roy. C. (2011). Extending the Roy Adaptation Model to meet changing global needs. 
Nursing Science Quarterly, 24(345). doi.org/10.1177/0894318411419210 
Thomas, C. (2007). The influence of self-concept on adherence to recommended health 
regimens in adults with heart failure. Journal of Cardiovascular Nursing, 22(5). 
doi.org/10.1111/j.1365-2648.2007.04489.x 
61 
U.S. Department ot Health and Human Services Agency for Healthcare Research and 
Quality. (2012). Retrieved from http://qualitvindicators.ahrq.gov 
Venes. D. (Ed.). (2001). Tuber's cyclopedic medical dictionary (19th Ed.). Philadelphia, 
PA: F.A. Davis. 
Wier, L., Maeda. J.. Ryan. K.. Pfuntner, A., Stranges, E., Jagadish, P., . . . . Elixhauser, 




2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and 
Management of Heart Failure in Adults (pp. 1985-1987) 
Jessup et al 2009 Guideline Focused Update on Heart Failure 1985 
to exclude the presence of primary valve disease. Secondary 
changes in valve function, particularly the severity of mitral and 
tricuspid valve insufficiency, should be determined. 
Noninvasive hemodynamic data acquired at the time of 
echocardiography are an important additional correlate for 
patients with preserved or reduced EF. Combined quanti­
fication of the mitial valve inflow pattern, pulmonary 
venous inflow pattern, and mitral annular velocity provides 
data about characteristics of LV tilling and left atrial 
pressure. Evaluation of the tricuspid valve regurgitant 
gradient coupled with measurement of inferior vena caval 
dimension and its response during respiration provides an 
estimate of systolic pulmonary artery pressure and central 
venous pressure. Stroke volume may be determined with 
combined dimension measurement and pulsed Dcrpplcr in the 
LV outflow tract.21 However, abnormalities can be present in 
any of these parameters in the absence of HF. No single 
parameter necessarily correlates specifically with HF; however, 
a totally normal filling pattern argues against clinical HF. 
A comprehensive echocardiography evaluation is important, 
because it is common for patients to have more than L cardiac 
abnormality thai contributes to the development of HF. Further­
more, the study may serve as a baseline for comparison, because 
measurement of EF' and the severity of structural remodeling can 
provide useful information in patients who have had a change in 
clinical status or who have experienced or recovered from a 
clinical event or received treatment that might have had a 
significant effect 011 cardiac function. 
Other tests may be used to provide information regarding 
the nature and severity of the cardiac abnormality. Radionu­
clide ventriculography can provide highly accurate measure­
ments of LV function and right ventricular EF, but it is unable 
to directly assess valvular abnormalities or cardiac hypertro­
phy. Magnetic resonance imaging or computed tomography 
may be useful in evaluating chamber size and ventricular 
mass, detecting right ventricular dysplasia, or recognizing the 
presence of pericardial disease, as well as in assessing cardiac 
function and wall motion.25 
Magnetic resonance imaging may also be used to identify 
myocardial viability and scar tissue.26 Chest radiography can be 
used to estimate the degree of cardiac enlargement and pulmo­
nary congestion or to detect the presence of pulmonary disease. 
A 12-lead electrocardiogram may demonstrate evidence of prior 
Ml, LV hypertrophy, cardiac conduction abnonnality (e.g., left 
bundle-branch block), or a cardiac arrhythmia. However, be­
cause of their low sensitivity and specificity, neither the chest 
x-ray nor the electrocardiogram should form Lhe primary basis 
for determining the specific cardiac abnoimality responsible for 
the development of HF. 
3.1.3.2. Laboratory Testing 
Laboratory testing may reveal the presence of disorders or 
conditions that can lead to or exacerbate HF. The initial 
evaluation of patients with HF should include a complete 
blood count, urinalysis, scrum electrolytes (including calcium 
and magnesium), glycohemoglobin, and blood lipids, as well 
as tests of both renal and hepatic function, a chest radiograph, 
and a 12-lcad electrocardiogram. Thyroid function tests 
(especially thyroid-stimulating hormone) should be mea-
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surcd, because both hyperthyroidism and hypothyroidism can 
be a primary or contributory cause of HF. A fasting trans­
ferrin saturation is useful to screen for hemochromatosis; 
several mutated alleles for this disorder are common in 
individuals of Northern European descent, and affected pa­
tients may show improvement in LV function after treatment 
with phlebotomy and chelating agents. Magnetic resonance 
imaging of the heart or liver may be needed to confirm the 
presence of iron overload. Screening for human immunode­
ficiency virus (HIV) is reasonable and should be considered 
for all high-risk patients. However, other clinical signs of 
HIV infection typically precede any HF symptoms in those 
patients who develop HIV cardiomyopathy. Serum titers of 
antibodies developed in response to infectious organisms are 
occasionally measured in patients with a recent onset of HF 
(especially in those with a recent viral syndrome), but the 
yield of such testing is low, and Lhe therapeutic implications 
of a positive result arc uncertain (sec a recent review of the 
role of endomyocardial biopsy,13 and Section 3.1.3.4, Eval­
uation of the Possibility of Myocardial Disease, in the 
full-text guideline. Assays for connective tissue diseases and 
for phcochromocytoma should be performed if these diag­
noses are suspected, and serum titers of Chagas disease 
antibodies should be checked in patients with nonischemic 
cardiomyopathy who have traveled in or emigrated from an 
endemic region. 
Several recent assays have been developed for natriuretic 
peptides (BNP and NT-proBNP). Several of the natriuretic 
peptides arc synthesized by and released from the heart. 
Elevated plasma BNP levels have been associated with 
reduced LVEF,27 LV hypertrophy, elevated LV filling pres­
sures, and acute MT and ischemia, although they can occur in 
other settings, such as pulmonary embolism and chronic 
obstructive pulmonary disease. 
Natriuretic peptides tire sensitive to other biological 
factors, such as age, sex, weight, and renal function.25 
Elevated levels lend support to a diagnosis of abnormal 
ventricular function or hemodynamics causing symptom­
atic HF.29 Trials with these diagnostic markers suggest use 
in the urgcnt-carc setting, where they have been used in 
combination with clinical evaluation to differentiate dys­
pnea due 10 HF from dyspnea of other causes," and suggest 
that its use may reduce both the lime to hospital discharge 
and the cost of treatment.30 BNP levels tend to be less 
elevated in HF with preserved EF than in HF with low EF 
and are lower in obese patients.31 32 Levels of natriuretic 
peptides may be elevated meaningfully in women and in 
people over 60 years of age who do not have HF, and thus 
these levels should be interpreted cautiously in such 
individuals when distinguishing between cardiac and non-
cardiac causes of dyspnea. Elevated natriuretic peptide 
levels may lend weight to a suspected diagnosis of HF or 
trigger consideration of HF when the diagnosis is unknown 
but should not be used in isolation to confirm or exclude 
the presence of HF.30-33 
3.2.3. Laboratory Assessment 
Serum electrolytes and renal function should be monitored 
routinely in patients with HF. Of particular importance is the 
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serial measurement of serum potassium concentration, be­
cause hypokalemia is a common adverse effect of treatment 
with diuretics and may cause fatal arrhythmias and increase 
the risk of digitalis toxicity, whereas hyperkalemia may 
complicate therapy with angiotensin-converting enzyme 
(ACEl inhibitors, angiotensin II receptor blockers (ARBs), 
and aldosterone antagonists. Worsening renal function may 
require adjustment of the doses of diuretics, rcnin-
angiotensin-aldostcronc system antagonists, digoxin, and 
noncardiac medications. Development of hyponatremia or 
anemia may be a sign of disease progression and is associated 
with impaired survival. 
Scrum BNP levels have been shown to parallel the clinical 
severity of HF as assessed by NYHA class in broad popula­
tions. Levels are higher in hospitalized patients and tend to 
decrease during aggressive therapy for decompensation (see 
Section 3.1.3.2. in the full-text guideline, Laboratory Test­
ing).^ Indeed, there is an increasing body of evidence 
demonstrating the power of the addition of BNP (or NT-
proBNP) levels in the assessment of prognosis in a variety of 
cardiovascular disorders. However, it cannot be assumed that 
BNP levels can be used effectively as targets for adjustment 
of therapy in individual patients. Many patients taking opti­
mal doses of medications continue to show markedly elevated 
levels of BNP, and some patients demonstrate BNP levels 
within the normal range despite advanced HF. The use of 
BNP measurements to guide the titration of drug doses has 
not been shown conclusively to improve outcomes more 
effectively than achievement of the target doses of drugs 
shown in clinical trials to prolong life.3*' Ongoing trials will 
help to determine the role of serial BNP (or other natriuretic 
peptides) measurements in both diagnosis and management 
of HF. 
Serial chest radiographs are not recommended in the 
management of chronic HF*. Although the cardiothoracic ratio 
is commonly believed to reflect die cardiac dilatation thai is 
characteristic of HF, enlargement of the cardiac silhouette 
primarily reflects changes in right ventricular volume rather 
than LV function, because the right ventricle forms most of 
the border of dilated hearts on radiographs. Similarly, 
changes in the radiographic assessment of pulmonary vascu­
lar congestion arc too insensitive to detect any but the most 
extreme changes in fluid status.35 
Repeat assessment of EF may be most useful when the 
patient has demonstrated a major change in clinical status. 
Both improvement and deterioration may have important 
implications for future care, although the recommended 
medical regimen should be continued in most cases. Improve­
ment may reflect recovery' from a previous condition, such as 
viral myocarditis or hypothyroidism, or may occur after 
titration of recommended therapies for chronic HF*. Thus, it is 
appropriate to obtain a repeat EF after some period of optimal 
medical therapy, typically 4 to 6 months, to decide about the 
implantation of an implantable cardioverter-defibrillator 
(ICD) Deterioration may reflect gradual disease progression 
or a new event, such as recurrent MI. Routine assessment of 
EF at frequent, regular, or arbitrary intervals is not recom­
mended. 
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There has been no established role for periodic invasive or 
noninvasive hemodynamic measurements in the management 
of HF. Most drags used for the treatment of HF are prescribed 
on the basis of their ability to improve symptoms or survival 
rather than their effect on hemodynamic variables. Moreover, 
the initial and target doses of these drugs are selected on the 
basis of experience in controlled trials and are not based on 
the changes they may produce in cardiac output or pulmonary 
wedge pressure. Nevertheless, invasive hemodynamic mea­
surements may assist in the determination of volume status 
and in distinguishing HF from other disorders that may cause 
circulatory instability, such as pulmonary diseases and sepsis. 
Measurements of cardiac output and pulmonary wedge pres­
sure through a pulmonary artery catheter have also been used 
in patients with refractory HF to assess pulmonary vascular 
resistance, a determinant of eligibility for heart transplanta­
tion. Cardiac output can also be measured by noninvasive 
methods. 
3.2.4. Assessment of Prognosis 
Although both healthcare providers and patients may be 
interested in defining the prognosis of an individual patient 
with HF, the likelihood of survival can be determined reliably 
only in populations and not in individuals. However, some 
attempt at prognostication in HF may provide better informa­
tion for patients and their families to help them appropriately 
plan for their futures. It also identifies patients in whom 
cardiac transplantation or mechanical device therapy should 
be considered. 
Multivariate analysis of clinical variables has helped to 
identify the most significant predictors of survival, and prognos­
tic models have been developed and validated.36 Decreasing 
LVEF, worsening NYHA functional status, degree of hypona­
tremia, decreasing peak exercise oxygen uptake, decreasing 
hematocrit, widened QRS on 12-lead electrocardiogram, chronic 
hypotension, resting tachycardia, renal insufficiency, intolerance 
to conventional therapy, and refractory volume overload are all 
generally recognized key prognostic parameters, although the 
actual prognostic models incorporating them are not widely used 
in clinical practice.36-37 Although elevated circulating levels of 
neurohormonal factors have also been associated with high 
mortality rates, the routine assessment of neurohormones such as 
norepinephrine or endothelin is neither feasible nor helpful in 
clinical management. Likewise, elevated BNP (or NT-proBNP) 
levels predict higher risk of HF and other events after MI. 
whereas marked elevation in BNP levels during hospitalization 
for HF may predict rehospitalizafion and death. Nonetheless, the 
BNP measurement has not been clearly shown to supplement 
careful clinical assessment for management 
Because treatment of HF has improved over the past 10 years, 
the older prognostic models need to be revalidated,33 and newer 
prognostic models may have to be developed. Outcomes have 
been improved for most high-risk patients, which has resulted in 
a shift in the selection process for patients referred for heart 
transplantation.33 Routine use of ambulatory electrocardio­
graphic monitoring, T-wavc altemans analysts, heart rate vari­
ability measurement, and signal-averaged electrocardiography 
have not been shown to provide incremental value in assessing 
overall prognosis, although ambulatory electrocardiographic 
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monitoring can be useful in decision making regarding place­
ment of ICDs.34 
4. Therapy 
4 3 1  •  P a t i e n t s  W i t h  R e d u c e d  L e f t  V e n t r i c u l a r  E j e c t i o n  
Fraction 
Changes m this section focused on 3 areas: recommendations about 
electrical device therapy (e.g., cardiac resynchronization therapy 
[CRT] and ICDs), the use of a fixed dose combination of 
hydralazine and isosorbide dinitrate in self-identified African 
Americans, and the management of atrialfibrillation in patients 
with IFF. The previous version of the guidelines had a number of 
possibly confusing recommendations about selection ofpatients for 
ICD implantation. The -writing group has tried to simplify the 
recommendations, ami keep them concordant with the most recent 
guidelines covering the same issued9^ Updated trial information 
has led to the change in the recommemlations about the use of 
hydralazineAsosorbide dinitrate and about the management of 
atrialfibrillation (Table 3). 
4.3.1.1. General Measures 
Measures listed as Class I recommendations for patients in 
stage A or B are also appropriate for patients with current or 
prior symptoms of HF (also see Section 5, Treatment of 
Special Populations). In addition, moderate sodium restric­
tion, along with daily measurement of weight, is indicated to 
permit effective use of lower and safer doses of diuretic drugs, 
even if overt sodium retention can be controlled by the use of 
diuretics. Immunizarion with influenza and pneumococcal 
vaccines may reduce the risk of a respiratory infection. 
Although most patients should not participate in heavy labor 
or exhaustive sports, physical activity should be encouraged 
(except during periods of acute exacerbation of the signs and 
symptoms of HF. or in patients with suspected myocarditis), 
because restriction of activity promotes physical decondition-
ing. which may adversely affect clinical status and contribute 
to the exercise intolerance of patients with HF.,4a-,4S 
Three classes of drugs can exacerbate the syndrome of HF 
and should be avoided in most patients: 
1. Antiarrhythmic agents'4* can exert important cardiodc-
pressant and proarrhythmic effects. Of available agents, 
only amiodaronc and dofetilide147 have been shown not to 
adversely affect survival. 
2. Calcium channel blockers can lead to worsening HF and 
have been associated with an increased risk of cardiovas­
cular events.148 Of available calcium channel blockers, 
only the vasoselective ones have been shown not to 
adversely affect survival.'34'144 
3 Nonsteroidal anti-inflammatory dings can cause sodium 
retention and peripheral vasoconstriction and can attenuate 
the efficacy and enhance the toxicity of diuretics and ACE 
inhibitors.84-87 A discussion of the use of aspirin as a 
unique agent is found later in this section (sec Section 
4.3 1.2.2.1., Angiotensin Converting Enzyme Inhibitors 
in the Management of Heart Failure, in the full-text 
guideline). 
Patients with HF should be monitored carefully for 
changes in serum potassium, and every effort should be made 
to prevent the occurrence of either hypokalemia or hyperka­
lemia, both of which may adversely affect cardiac excitability 
and conduction and may lead to sudden death.'50 Activation 
of both the sympathetic nervous system and renin-angiotensin 
system can lead to hypokalemia,'51-152 and most drugs used 
for the treatment of HF can alter serum potassium.153 Even 
modest decreases in scrum potassium can increase the risks of 
using digitalis and antiarrhythmic drugs,'50-154 and even 
modest increases in serum potassium may prevent the use of 
treatments known to prolong life.'55 Hence, many experts 
believe that scrum potassium concentrations should be tar­
geted in the 4.0 to 5.0 mmol per liter range. In some patients, 
correction of potassium deficits may require supplementation 
of magnesium and potassium.156 In others (particularly those 
taking ACH inhibitors alone or in combination with aldoste­
rone antagonists), the routine prescription of potassium salLs may 
be unnecessary and potentially deleterious. 
Of the general measures that should be used in patients 
with HF, possibly the most effective yet least used is close 
observation and follow-up. Nonadherents with diet and 
medications can rapidly and profoundly affect the clinical 
status of patients, and increases in body weight and minor 
changes in symptoms commonly precede by several days the 
occurrence of major clinical episodes that require emergency 
care or hospitalization. Patient education and close supervi­
sion, which includes surveillance by the patient and his or her 
family, can reduce the likelihood of nonadherence and lead to 
the detection of changes in body weight or clinical status 
early enough to allow the patient or a healthcare provider an 
opportunity to institute treatments that can prevent clinical 
deterioration. Supervision need not be performed by a phy­
sician and may ideally be accomplished by a nurse or 
physician's assistant with special training in the carc of 
patients with HF. Such an approach has been reported to have 
significant clinical benefits.157-160 
Recommendations Concerning Aldosterone Antagonists. The 
addition of low-dose aldosterone antagonists is recommended 
in carefully selected patients with moderately severe or 
severe HF symptoms and recent decompensation or with LV 
dysfunction early after Mr. These recommendations are based 
on the strong data demonstrating reduced death and rehospi-
taliz.ation in 2 clinical trial populations.'55-'6' The entry 
criteria for these trials describe a broader population than was 
actually enrolled, such that the favorable efficacy/ toxicity 
ratio may not be as applicable to patients at the margins of 
trial eligibility. For both of these major trials, patients were 
excluded for a serum creatinine level in excess of 2.5 mg per 
dL, but few patients were actually enrolled with serum 
creatinine levels over 1.5 mg per dL. In the trial of patients 
after MI. there was a significant interaction between scrum 
creatinine and benefit of cplcrenonc. The average serum 
creatinine of enrolled patients was 1.1 mg per cIL, above 
which there was no demonstrable benefit for survival. 
To minimize the risk of lifc-thrcatcning hyperkalemia in 
patients with low LVEF and symptoms of HF, patients should 
have initial serum creatinine less than 2.0 to 2.5 mg per dL 
without recent worsening and serum potassium less than 5.0 
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Heart Failure in Adults 2011 (p. 15) 
using either continuous infusion or bolus intravenous injections [Meta-Analysis], 
In acute decompensated heart failure, there also has been shown to be no 
difference in the use of low dose (equivalent to the patient's previous oral dose) 
or high dose (2.5 times the previous oral dose) in terms of the patient's global 
assessment of symptoms or in the change in renal function. Therefore, no 
benefit is seen to either low versus high dose or infusion versus bolus injection 
as long as adequate natriuresis is maintained. 
• Sodium, Potassium, Chloride/Bicarbonate, BUN/Scr (basic chemistry 
panel) 
• Before diuretic initiation 
• During the diuretic initiation phase, the first lab after starting therapy is 
dependent on the degree of diuresis: 
• Outpatients on oral diuretic therapy should have their labs 
repeated once approximately five to seven days after diuretic 
initiation. If lab abnormalities are present, labs should be 
repeated weekly until they have stabilized. 
• Inpatients on large intravenous (IV) doses of diuretics 
(including drips) or who require frequent dose changes should 
have labs repeated daily at a minimum. 
• Following the initiation phase, stable outpatient diuretic patients should 
have a basic chemistry panel drawn every four months for the duration 
of therapy. If any of the following occurs, lab monitoring will need to be 
more frequent until the patient stabilizes: 
• Changes in diuretic dose, route, or frequency 
• The patient's condition worsens 
• The patient develops signs/symptoms of electrolyte 
abnormalities 
• If lab abnormalities are found at any time, increased lab surveillance is 
warranted until levels have normalized. 
• Magnesium, Calcium 
. Before diuretic initiation, then every four months for the duration of 
therapy 
• Glucose Checks (diabetic patients) 
• Before diuretic initiation 
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APPENDIX D 
Letter ot Consent for Participation in a Research Study 
January 28, 2013 
Dear Healthcare Provider, 
\\ e are graduate students in the Family Nurse Practitioner Program at Mississippi 
I niveisity for Women in Columbus, MS. As a program requirement for graduation, we 
aie conducting a quality assurance research study to assess compliance of 
recommendations for monitoring potassium from the American College of Cardiology 
Foundation/American Heart Association (ACCF/AHA) and the Institute for Clinical 
Systems Improvement guidelines for heart failure in adults. Potassium is one of our 
body s main intracellular electrolytes, which could cause an adverse cardiac event if the 
level is not monitored and kept in the acceptable range for this diagnosis. The results of 
this study will improve the healthcare provider's adherence to the 2009 ACCFAHA 
guidelines in the care ot heart failure patients, enhancing patient outcomes and decreasing 
the potential of life-threatening complications. 
We would like to use your facility's charts for compiling data for this study. Your 
participation will involve granting us the privilege of reviewing 100 medical records of 
your patients 18 years of age and older with ICD-9 diagnosis code 428 for heart failure. 
We agree to refrain from discussing or disclosing any information regarding your clients. 
All information acquired from this retrospective chart review would be completely 
confidential. Neither names of patients nor the facility name will be used in the study. 
Each researcher will receive HIPAA and Corporate Compliance training through the 
facility before beginning the research. The chart reviews will be recorded on a data 
collection worksheet. The information will be entered into a computer data sheet for 
preparation of statistical analysis and saved to a password-protected media drive. The 
media drive and worksheets will be destroyed at the end of the study. The facility may 
withdraw at any time and participation is voluntary. Results of this research study will 
be shared with each facility and provider. Specific providers will not be named, and data 
will be resulted as a group. 
If you would like any further information, please feel free to contact Lori Duke at (662) 
882-0798 or lduke2009@yahoo.com, Cindy Patrick (601) 513-2337 or 
Cpatrickmuw2012 @gmail.com, or contact the chair of our research committee, Dr. 
Sueanne Davidson, at (662) 329-7322 or Sdavidson@nsgslp.muw.edu. Thank you for 
your willingness to consider this request. 
Sincerely, 
Lori Duke, RN, BSN 
Cindy Patrick, RN, BSN, CCRN 
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APPENDIX E 
Data Collection Worksheet 
Date of chart review 
1. Patient's gender: Male (1) Female (2) 
2. Patient's age years 
3. Ethnicity: 
Caucasian (1) African-American (2) Hispanic (3) 
Other (4) 
4. Was a serum potassium level checked in the last four months? 
Yes (1) No (2) 
5. Was the last serum potassium level between 4.0-5.0 mEq/L? 
Yes (1) No (2) 
6. Was a medication adjustment made if the serum potassium level was not in the 4.0-
5.0 mEq/L range? 
Yes (1) No (2) 
7. Is this patient on any of the following medications? 
ARB (1) ACE-I (2) Aldosterone Antagonist (3) 
Beta-blockers (4) Diuretic (loop, thiazide, or potassium-sparing) (5) 
8. What was the payer source? 
Medicare (1) Medicaid (2) commercial (3) 
Self-pay (4) 
